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Thesis Abstract 
There has been increased focus in improving the quality of care provided by health systems. One of the 
strategy that has gained prominence as a tool for improving quality of care is the development and 
implementation of clinical practice guidelines (CPGs). CPGs have become commonplace in clinical 
settings due to the view that they can improve the quality of care provided by promoting practices of 
proven benefit and improving consistency in clinical practice.  
 
The increased use of CPGs in both developed and developing countries has been, deservedly, 
accompanied by calls for evaluations of their efficiency. A review of literature, however, reveals that 
there are few economic evaluations of interventions that target change in clinical practice by promoting 
the uptake of CPGs. The few evaluations that are available are characterized by methodological 
problems. This is essentially because CPG implementation is a complex intervention.  
 
The economic evaluation of complex CPG implementation is associated with a number of 
methodological challenges. These issues include challenges in defining the intervention and the 
counterfactual and consensus on the relevant range of costs to be included in the analysis. The greatest 
challenge, however, lies in how to define an appropriate measure of effectiveness to be used as the 
outcome in economic evaluation. This includes challenges in incorporating process measures of service 
quality as measures of effectiveness. Questions on which measures to use, how multiple measures 
might be combined, how improvements in one area might be compared with those in another and what 
value is associated with improvement in health worker practices are yet to be answered.   
 
In Kenya, an intervention to improve the quality of care of children was developed and tested in district 
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supervision, feedback and facilitation, for brevity called the Emergency Triage and Treatment Plus 
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Part A: Study Protocol 
Costs and Effects of a Multifaceted Intervention to Improve the Quality of Care of Children in District 
Hospitals in Kenya 
Background 
An estimated 8.8 million children die globally every year before age five (You et al., 2009, Black et al., 
2010). Ninety nine percent of these deaths occur in developing countries, with fifty percent in Sub-
Saharan Africa (You et al., 2009). In Kenya the under five mortality rate was 74 per 1000 children in 2008 
(Kenya National Bureau of Statistics (KNBS) and ICF Macro, 2010). A series of reports by the Bellagio 
research group reveal that most of these deaths are due to a few treatable and preventable diseases, 
for which effective interventions are already available (Black et al., 2003, Jones et al., 2003, Bryce et al., 
2003, Claeson et al., 2003, Victora et al., 2003). Effective provision of an essential package of 
interventions, at scale, is felt to be critical in achieving Millennium Development Goal 4 (MDG 4) which 
calls for a two thirds reduction in the under five mortality rate between 1990 and 2015 (Bryce et al., 
2006, Bryce et al., 2008, Veneman, 2006). Kenya’s under five mortality rate was 97 per 1000 live births 
in 1990 and rose to 121 per 1000 live births by 2006 (Ayieko et al., 2009). The under five mortality rate 
then decreased to 74 per 1000 live births by 2008; this improvement has been attributed in part to 
improved coverage of key child health interventions, notably immunization, distribution of insecticide 
treated nets (ITNs) for malaria prevention and malaria case management in health facilities (Kenya 
National Bureau of Statistics (KNBS) and ICF Macro, 2010). To meet the millennium development goal 
target however, this rate will need to reduce further to 32 per 1000 live births by 2015.   
While it is generally accepted that many child survival interventions need to be implemented at the 
community or primary care level, delivery of case management interventions for the severely ill child 
largely depends on the presence of functioning rural (district) hospitals. It has been observed that if 
functioning well, rural (district) hospitals can make an important contribution to child survival by 
reducing child mortality by 44% in the areas they serve, compared to the absence of any hospital 
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in developing countries has been found to be poor and in need of considerable improvement (English et 
al., 2004a, English et al., 2004b). One strategy for improving the delivery of care is the development and 
implementation of evidence based clinical practice guidelines (CPGs) (Irimu et al., 2008). Clinical practice 
guidelines are systematically developed statements to assist both practitioner and patient decisions in 
specific circumstances (Eccles and Mason, 2001). CPGs have become an increasingly familiar part of 
clinical care and are viewed as useful tools for promoting the use of beneficial interventions, making 
care more consistent and, on occasion, less costly (Eccles and Mason, 2001). Their use has been shown 
to be effective in improving quality of care and patient outcomes (Schellenberg et al., 2004, Arifeen et 
al., 2005, Amorim et al., 2008, Naimoli et al., 2006). Benefits have been demonstrated both for 
interventions targeting single conditions such as pneumonia (Menendez et al., 2002, Menendez et al., 
2007, Nathwani et al., 2001, Martinez et al., 2009), hypertension (Milchak et al., 2004) and diabetes 
(McRae et al., 2008), or multiple interventions targeting a number of high-burden conditions; the 
Integrated Management for Childhood  Illnesses (IMCI) is one such intervention (Schellenberg et al., 
2004, Rowe et al., 2009). However, the effectiveness of clinical interventions is dependent on, among 
other things, their delivery strategies (Grimshaw et al., 2006, Vale et al., 2007, Prior et al., 2008, English 
et al., 2008). Studies in both high and low-income countries have shown that providing CPGs alone yields 
little effect, and that multifaceted interventions including, for example, training, feedback and 
supervision are more effective than single interventions (Grimshaw et al., 2006, Davis et al., 1995, 
English et al., 2008, Prior et al., 2008, Pariyo et al., 2005).  
All interventions are associated with costs. In a resource constrained environment, we are increasingly 
challenged to justify resource allocation in terms of costs and effects. This has led to an expansion of the 
literature on cost effectiveness of health interventions in developing countries around vaccines (Akumu 
et al., 2007, Valencia et al., 2008), HIV/AIDS interventions (Hogan et al., 2005), insecticide treated nets 
(ITNS) and other malaria interventions (Guyatt et al., 2002, Wiseman et al., 2003, Goodman et al., 2006) 
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clinical guidelines, it is imperative that they too be subjected to rigorous evaluation of their costs and 
consequences. Information on the costs and effects will also be useful in modeling the scale up of the 
intervention to increase access for the population in need. 
  
Systematic reviews conducted to evaluate the effectiveness of guideline implementation have shown 
that most studies are of poor quality and the findings are difficult to generalize to other settings (Prior et 
al., 2008, Grimshaw and Russell, 1993, Grimshaw et al., 2004, Grimshaw et al., 2006, Vale et al., 2007, 
Hoomans et al., 2007).  Economic analyses related to such studies are particularly poor. In a systematic 
review by Grimshaw et al, of the 235 studies evaluated, only 29.4 %  reported any economic data, and 
overall, the methods of the economic evaluations and cost analyses were poor (Grimshaw et al., 2004). 
Major weaknesses included the lack of transparency in costing methodology, omission of intervention 
development costs and difficulty in defining appropriate effectiveness measures for complex 
interventions. Subsequent systematic reviews have revealed the same weaknesses (Prior et al., 2008, 
Hoomans et al., 2007). 
 
These findings reveal gaps in guideline implementation evaluation methodology and underscore the 
need for more rigorous studies. In the area of child health interventions, the multi country evaluation 
(MCE) of the Integrated Management of Childhood Illnesses (IMCI) offers a suggested methodology for 
evaluation of the effectiveness and costs of guideline implementation (WHO, 2003).  However, 
methodological questions that still remain unanswered include: 
  
 What is the relevant scope of costs that should be considered in the economic evaluation of 
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 What is an appropriate measure of effectiveness for complex health interventions such as the usage 
of clinical guidelines where conventional measures such as mortality, DALYs or QALYs may either not 
suffice or may not be measurable? 
 
This thesis therefore aims to contribute to the developing field of economic evaluation of complex 
interventions. Specifically it will involve the examination of the costs and consequences of a 
multifaceted intervention to improve the quality of care of children in district hospitals in Kenya. The 
work will involve the development of an explicit, comprehensive costing approach clearly identifying 
development costs and implementation costs. Of interest will be the costs that are considered by 
stakeholders to be relevant for decision making and those that form the basis for modeling scaling-up.  
 
The work will also involve a cost effectiveness analysis, where effectiveness of the intervention is 
evaluated using selected process of care measures that constitute indicators of quality of care. 
Additionally the work will involve the modeling of scale up costs and budget impact of the intervention if 
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Aims of the Study 
Broad Objective 
The broad objective of the study is to conduct a cost effectiveness analysis of a multifaceted 
intervention to improve the delivery of evidence based care for severely ill children in district hospitals 
in Kenya. 
The Intervention 
This was an 18 month hospital based, multifaceted intervention aiming to promote adherence to new, 
evidence-based clinical practice guidelines (CPGs) for management of seriously ill newborns and children 
admitted to hospitals. The clinical practice guidelines were developed or adapted from existing WHO 
guidance. A training course linked to the CPGs and also adapted from the existing WHO Emergency 
Triage, Assessment and Treatment (ETAT) course was developed. This new course included a 
considerable amount of new material on newborn resuscitation and the common causes of serious 
illness in the newborn or child and has therefore was called ‘‘Emergency Triage Assessment and 
Treatment Plus Admission Care’’ (ETAT+) (English et al., 2008, Irimu et al., 2008).  
 
This training, conducted over 5.5 days, and augmented by provision of CPG booklets, job aids and 
pediatric admission records (PAR) was used to initiate the intervention. The pediatric admission record 
(PAR) is a structured form used by clinicians to document a sick child’s clinical information on admission. 
The PAR was designed to capture key symptoms for common childhood illnesses (malaria, pneumonia, 
diarrhea and dehydration, meningitis, malnutrition and HIV/AIDS) as well as signs and approaches to 
severity classification and other facility information needs (Mwakyusa et al., 2006).  
 
This was then followed by supervision in the form of 2-3 monthly visits, reports, ad hoc follow up 
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calls. Detailed surveys of hospital practices were conducted pre-intervention and at 6 monthly intervals 
thereafter. Results were fed back to intervention hospitals in face to face meetings and by distributing 
written reports. In the 4 control hospitals, only CPG booklets, initial lectures in the form of a 1.5 day 
seminar and surveys followed by written reports were provided. These hospitals did not receive any 
quality improvement facilitation. The specific components of the intervention are outlined in detail 
elsewhere (English et al., 2008, Irimu et al., 2008) with the delivery schedule outlined in Figure 1.  
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Specific Objectives 
1. To determine the total economic cost of delivering the intervention to intervention hospitals in 
comparison to control hospitals where a partial version of the intervention was delivered 
2. To develop of a summary measure of quality of care to be used as the measure of effectiveness in 
the cost effectiveness analysis 
3. To undertake a cost effectiveness analysis of the intervention as delivered in intervention hospitals 
compared to a partial version of the intervention in control hospitals 
4. To model the costs of scaling up the intervention in Kenya and to determine the impact this scale up 
will have on the child health budget 
Methods and Analysis 
Study Design 
This shall be a cost effectiveness analysis alongside a cluster randomized trial.  
 
Perspective 
A provider perspective will be adopted. 
 
Time Horizon  
The time horizon will be the development, implementation and follow up period of the intervention 
(September 2006 – April 2008).  
 
Data Collection and Sample Sizes 
This cost effectiveness analysis is a sub-component of a parent study that evaluated a multifaceted 
intervention to improve the quality of care of children in district hospitals in Kenya. This parent study 
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randomized into 4 control and 4 intervention hospitals, with the intervention hospitals receiving the full 
package of the interventions while the control hospitals received a partial version (Ayieko et al., 2011).  
To evaluate any changes in costs and any changes in outcomes through CPG implementation, data on 
clinical performance and resource use were collected by clinical record review of children aged 2-59 
months, admitted to these hospitals with common, acute illnesses. Data were collected through 
baseline cross-sectional surveys in both intervention and control hospitals, and follow-up surveys at six-
monthly intervals. In total there were 6 surveys in the intervention hospitals, and 4 surveys in the 
control hospitals. The reason for the two additional surveys in intervention hospitals was to observe 
whether the intervention effects were sustained beyond the follow up period. Resource use data were 
collected by patient record review using patient case-record data abstraction forms (appendix 1). Data 
collected that are relevant to the costing component include medicines prescribed to patients and their 
quantities, laboratory investigations conducted, fluids administered to the patients and length of stay of 
patients in the hospital. 
 
To identify clinical records for evaluation, calendar dates were randomly sampled from the 6 month 
period prior to a survey and only records from children admitted on these days were retrieved.  The 
proportion of calendar dates sampled was adjusted to yield approximately 400 records per hospital per 
survey based on each hospital’s daily admission rates. The data collected did not require personal 
identifiers of patients or health workers, each were identified by unique codes and hence patient and 
respondent confidentiality was preserved.  
 
The time spent by intervention implementers to implement the intervention was captured by a time 
quantification tool (appendix 2). This tool was in the form of a questionnaire administered to the 6 core 
intervention implementers. These 6 intervention implementers are employees of the intervention 
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Start up and implementation costs were obtained from a review of accounting records kept by the 
KEMRI-Welcome trust. These records included resources, quantities used and their monetary costs. This 
was done after obtaining official permission from KEMRI administration.  
 
Evaluating Costs 
Costing this guideline implementation study will follow accepted principles recommended for costing 
other health care interventions (Drummond, 2005). Given that a systematic review of 69 economic 
analyses of guideline implementation identified that guideline development costs were usually ignored 
while 11 reported only costs of implementation and 12 both implementation and treatment costs 
(Grimshaw et al., 2006) this study will take particular care to report costs of the three main stages (Vale 
et al., 2007): 
 The development of the guidelines 
 Implementation of the package of approaches used to support guideline introduction 
 Treatment costs 
The additional costs in the intervention hospitals, compared to the control hospitals will be determined 
for the intervention period of 18 months. Both the total and unit costs of the intervention will be 
determined. The total costs will be an aggregate of all the costs of the interventions, while the unit costs 
refer to the cost of a single output, such as cost per sick child treated or average cost per hospital 




In identifying the costs, an ingredients approach will be used (World Health Organization, 2003). This will 
seek to identify the specific resources (ingredients) used in the intervention, quantify them and to assign 
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Sources of Cost Data and Collection 
Data abstraction tools will be developed for the collection of costs and utilization of resources. Data 
sources to be used will include:  
 Accounting records for the project 
 KEMRI-Wellcome trust salary scales and per diem rates (subsistence costs) 
 Kenyan Ministry of Health salary scales and  per diem rates (subsistence costs) 
 Project diary and logs (dates, duration of time spent on activities and personnel involved) 
 Interviews with project implementers (personnel time allocation) 
 Intervention team travel logs (destinations and distances) 
 Market rates for services and prices for inputs (to estimate economic costs) 
 
Financial vs Economic Costs 
Financial costs differ from economic costs in that they represent the actual monetary outflow or 
expenditure on resources (Kumaranayake, 2000b). Financial costs therefore do not include costs that 
are not paid for such as donations. Where costs are paid for but at subsidized prices, financial costing 
reports these subsidized prices since they represent the actual monetary flow.  
 
Economic costs on the other hand are defined in terms of the alternative uses that have been forgone 
by employing a resource in a particular way (Drummond, 2005). This perspective recognizes the 
opportunity cost of using resources, as these resources are then unavailable for productive use 
elsewhere (Kumaranayake, 2000b). This approach will therefore value donated and subsidized goods at 
their actual market prices.  Examples of economic costs in the intervention include the opportunity cost 
of personnel time spent in the development and implementation of the intervention and venue costs for 
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Identifying Costs 
The intervention costs will be broadly categorized into four groups (Adam, 2004, Goodman et al., 2006): 
 
a) Development Costs 
Development costs include all resources attributed to the intervention from the time when the decision 
was made to develop and implement the intervention up to but excluding the initial hospital training. 
Development costs include the development of ETAT+ guidelines, adaptation of the guidelines, and 
preparation of training materials.  
 
 b) Hospital Start-up Costs 
Start-up costs include initial hospital training and purchase of equipment by the hospitals to facilitate 
compliance with the CPGs.  The opportunity costs for resources used in these activities will be 
evaluated. For example, the staff time used in attending meetings will be evaluated and a share of 
salaries will be attributed to the economic costs of the intervention. 
 
Since the development and hospital start-up costs will be incurred before the intervention begins while 
the benefits are spread over a long period (more than one year), they will be treated as a capital 
purchase that provides services over time. The equipment purchased to enable CPG implementation will 
be annualized over the expected life of the item. Other items (e.g. initial training) will be annualized over 
the expected life of the intervention as a whole. 
  
c) Follow-Up Costs  
These will include all the costs incurred after the start-up period until the end of the 18 month 
implementation period. Activities include follow up training, supervisory visits, telephone calls, feedback 
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d) Treatment Costs 
Treatment costs will be defined as the cost of provision of care to sick children from admission to 
discharge and will be computed as the sum of “hotel” costs, laboratory diagnosis and medicine costs. It 
is important to include these costs as it is likely that the implementation of CPGs will lead to changes in 
the costs associated with inpatient care for sick children. “Hotel”  unit cost estimates will be derived 
from the World Health Organization, “Choosing Interventions that are Cost Effective” (WHO CHOICE) 
estimates (World Health Organization, 2005). The WHO CHOICE estimates represent the “hotel” 
component of hospital costs, excluding drugs and diagnostic tests and including other costs such as 
personnel, capital and food costs. Laboratory unit cost estimates will be obtained from laboratory 
costing data for a local district hospital in Kenya (Kilifi District Hospital). Medicine unit costs will be 
obtained from data on medicines prices in the Kenyan market for 2009.  Utilization data on hospital 
length of stay, laboratory tests and medicines prescribed will be obtained from data extracted from 
clinical records reviewed during the study surveys.  
 
Presenting, Annualizing and Transferring Costs over Time 
Costs will be adjusted for inflation using an appropriate GDP deflator (Walker and Kumaranayake, 2002). 
Economic capital costs will be annualized to derive the equivalent annual economic costs of these items 
(Walker and Kumaranayake, 2002). A discount rate of 3% and the respective useful lives of the capital 
resources will be utilized to determine the annualization factors for capital resources. Costs will be 
presented in United States dollars (USD). Given the fluctuations in exchange rates within the time 
horizon, costs will first be converted from Kenyan Shillings (KES) to USD using the respective period’s 
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Evaluating Effectiveness 
Others in the research group are currently involved in evaluating intervention effectiveness by 
measuring changes in the structure and process of hospital care for sick children. Effect sizes for changes 
in these measures between baseline and post implementation will be determined by calculating the 
difference of differences between children treated in the intervention and control hospitals. These data 
will be extracted from clinical records during the study surveys. 
 
Cost Effectiveness Analysis 
Data on changes due to the intervention will be explored and literature reviewed with the aim of 
developing an effectiveness measure that best summarizes the range of process measures to 
incorporate into cost effectiveness analysis (CEA).  Possible approaches include developing a patient 
level summary variable based on key quality indicators that represents receipt of “appropriate or 
recommended care” allowing a cost effectiveness ratio of “cost per additional child receiving appropriate 
care” to be determined (figure 2) as in recent published work (Rowe et al., 2009). While QALYs or DALYs 
are often used to measure and compare outcomes in CEA, the main study was not powered to measure 
differences in mortality or morbidity. 
Figure 2 Calculating the Incremental Cost Effectiveness Ratio 
ICER = (Ci – Cc)/(Ei - Ec) 
Where 
Ci – Total cost in intervention hospital     
Cc – Total cost in control hospital   
Ei – Total number of children receiving appropriate care under intervention conditions   
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Sensitivity Analysis 
Given the potential uncertainty about the values of several estimated parameters, one way sensitivity 
analysis will be conducted to test the robustness of the conclusions to changes in key parameters within 
meaningful ranges (Walker and Fox-Rushby, 2001). For example, salaries of personnel involved could 
vary widely depending on the cadre of personnel and whether they are employed by the government or 
private sector. Parameters to be subjected to sensitivity analysis will include: 
 Intervention effectiveness 
 Salary levels 
 Hotel costs 
 Development costs 
Ethical Considerations 
The larger study, for which this analysis is a subcomponent, has already received ethical approval from 
the Kenya Medical Research Institute (KEMRI) ethical review board and the national ethical review 
board of Kenya. Ethical approval will also be sought from the University of Cape Town ethical review 
board.  The economic analysis will not seek to collect information from patients or their families, 
precluding the need for informed consent. Clinical record data will be anonymized to conceal the 
identity of the children whose clinical records will be used.  Findings of this economic analysis are likely 
to benefit the population of children in Kenya by influencing policymaker’s decisions on resource 
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Part B: Literature Review 
Costs and Effects of a Multifaceted Intervention to Improve the Quality of Care of Children in District 
Hospitals in Kenya 
Introduction  
There has been increased focus in improving the quality of care provided by health systems. One of the 
strategies that has gained prominence as a tool for improving quality of care is the development and 
implementation of clinical practice guidelines (CPGs) (Irimu et al., 2008). CPGs have the potential to 
improve the quality of care by encouraging the adoption of interventions of proven benefit (best 
practice) and discouraging ineffective practice (Grimshaw et al., 2004). The increased use of CPGs in 
both developed and developing countries has been, rightfully, accompanied by calls for evaluations of 
their effectiveness and efficiency in improving quality of care. Given that quality of care interventions, 
like other healthcare interventions, cost money, there is a need for economic evaluations of these 
interventions to inform policy makers on how best to use scarce resources to maximize benefits. 
Approaches to conducting economic evaluations f quality improvement interventions, including CPGs, 
is the subject of this literature review. 
 
An exploratory search of PubMed was done as the starting point of the literature search. This was 
followed by further searches in PubMed and websites of quality of care organizations based on 
identified key words from the exploratory search.  A manual search through the references of identified 
studies was also conducted. Finally articles and books about the methods of economic evaluation were 
included. 
 
This review is structured as follows. The first section seeks to lay out the definition and concept of 
quality of care and explore the use of clinical practice guidelines in improving quality of care. This is 
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developed and developing countries in improving the quality of care delivered to patients. This is 
followed by an examination of a conceptual framework for the economic evaluation of the 
implementation of quality improvement interventions that incorporate clinical practice guidelines 
(CPGs). The final section presents a discussion of the challenges that are associated with the economic 
evaluation of such interventions. 
 
Quality of Care  
The international organization of medicines (IOM) has defined quality of medical care as the degree to 
which health services increase the likelihood of desired health outcomes and are consistent with current 
professional knowledge (Institute of Medicine, 1990). Desired health outcomes is emphasized in this 
definition, highlighting the crucial link between how care is provided and its effect on health (Institute of 
Medicine National Roundtable on Health Care Quality 1998). The premise is that improving quality of 
care increases the likelihood of beneficial outcomes. Current professional knowledge underlines the 
importance of adopting and appropriately using current evidence and for the potential for such practice 
to change with the advent of new knowledge and approaches (Institute of Medicine National 
Roundtable on Health Care Quality 1998). 
  
Approaches to Evaluation of Quality of Care  
The most dominant framework for the evaluation of quality of care is the one proposed by  Donabedian 
(Donabedian, 2005). This framework proposes that quality of care should be measured in terms of the 
structure, process and outcomes of care, the so called “quality triad” as outlined in figure 3 
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Figure 3 Donabedian Triad for Quality Improvement 
The evaluation of structure involves the assessment of the availability of equipment and infrastructure
needed to provide care (Donabedian, 1969, Donabedian, 2005). For the provision of care for children
under five, structural aspects include the availability of medicines for management of common
childhood diseases, equipment such as either oxygen cylinders or concentrators, infant warming device
in the nursery, weighing scales for infants and laboratory services such as full hemogram tests,
measurements of bilirubin, blood glucose test and others (Opondo et al., 2009). The focus on structure
is based on the premise that a healthcare facility needs structural capacity to provide good care
(Donabedian, 2005). 
The evaluation of process involves an assessment of the provision of care (Donabedian, 2005, 
Donabedian, 1969). This is linked to the notion that a specified structural capacity can enable the 
provision of care of a particular quality. Process of care measures have been used to evaluate quality in 
child health with recent examples including the multicountry evaluation of the Integrated Management 
of Childhood Diseases (IMCI) (Bryce et al., 2004). Here process of care measures included child 
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The evaluation of outcomes consists of the assessment of the end results of medical care in terms of 
health outcomes (Donabedian, 1969, Donabedian, 2005). This includes patient outcomes such as 
recovery, mortality and morbidity (Donabedian, 1969, Donabedian, 2005). The extent to which desired 
health outcomes are achieved is the ultimate test of the assumptions for using structure and process 
measures to assess quality of care.   
 
The study under evaluation in this thesis evaluates and reports quality changes in terms of process of 
care measures that span assessment, diagnosis and treatment (Ayieko et al., 2011). The choice of 
process measures as opposed to outcome measures was informed by the observation that process 
measures are more suitable for assessing changes in hospital care compared to outcome measures for 
reasons that will be discussed in a latter section of this review.  
 
Clinical Practice Guidelines 
Clinical practice guidelines (CPGs) have been defined as systematically developed statements to assist 
practitioner and patient decisions on appropriate health care for specific clinical circumstances (Institute 
of Medicine Committee on Clinical Practice Guidelines, 1992, Prior et al., 2008). CPGs are perceived to 
be useful in improving quality of care by promoting the use of “best practice” and have thus become 
common in clinical practice (Eccles and Mason, 2001). 
  
While interest in the use of CPGs has been increasing (Grimshaw and Russell, 1993, Eccles and Mason, 
2001), the has been uncertainty about whether CPGs are effective in changing professional practice in 
ways that would improve quality of care and health outcomes (Grimshaw and Russell, 1993). This 
uncertainty is coupled with the fact that the development and adoption of CPGs costs money. This has 
led to attempts to evaluate the effectiveness and efficiency of clinical practice guidelines, and of 
alternative ways of implementing these guidelines, in improving quality of care (Grimshaw and Russell, 
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Do Clinical Guidelines Influence Clinical Practice? 
In developed countries, the benefits of guidelines have been demonstrated for interventions targeting 
single conditions such as pneumonia (Menendez et al., 2002, Menendez et al., 2007, Nathwani et al., 
2001, Martinez et al., 2009, Lancaster et al., 2008, Frei et al., 2006), hypertension (Milchak et al., 2004), 
diabetes (McRae et al., 2008) and asthma (Gazarian et al., 2001). Grimshaw and Russell undertook a 
systematic review of rigorous evaluations of clinical guidelines published between 1976 and 1992 
(Grimshaw and Russell, 1993). Out of the 59 studies included in the review, all but 4 of them reported 
significant improvement in the process of care (Grimshaw and Russell, 1993). Of the 11 studies that 
studied patient outcomes as the primary end point, all but 2 showed significant improvement in 
targeted outcomes (Grimshaw and Russell, 1993).  
 
In an updated review by Grimshaw and colleagues to include a further 32 studies up to 1994, 81 of the 
87 studies that investigated process of care showed significant improvement (Grimshaw et al., 1995). Of 
the 17 studies with patient outcomes as the primary endpoint, 12 showed significant improvement 
(Grimshaw et al., 1995). A subsequent systematic review by Grimshaw and colleagues of studies 
published between 1966 and 1998 that included 235 studies reported that 86.6% of the studies showed 
improvement in quality of care (Grimshaw et al., 2006).  
 
In developing countries, where rapid and far reaching changes are urgently required, clinical practice 
guidelines have been employed mostly as part of packages targeting conditions causing the greatest 
burden of disease; the Integrated Management for Childhood Illnesses (IMCI) is a good example (Bryce 
et al., 2005a, Bryce et al., 2005b, Arifeen et al., 2009). 
 
The multi-country evaluation (MCE) of IMCI provides useful insights into the effectiveness of CPGs and 
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et al., 2004, Huicho et al., 2005b, Amaral et al., 2004). IMCI has been adopted by over 80 countries as a 
strategy for reducing child mortality and improving child health and development (Schellenberg et al., 
2004b). This complex public health intervention incorporates training, case management (guidelines), 
multiple health system strengthening approaches and a community component. MCE-IMCI studies in 
Tanzania, Brazil, Peru, Bangladesh and Uganda reported that in all settings where case management 
training was implemented and where sufficient coverage of trained health workers was achieved, the 
quality of care improved (Amaral et al., 2004, Schellenberg et al., 2004b, El Arifeen et al., 2004, Gouws 
et al., 2004).  The evidence from these rigorous evaluations strongly suggests that properly developed 
guidelines can change clinical practice and may lead to changes in patient outcome.  
  
Introducing Guidelines into Practice 
The uptake of clinical practice guidelines by health care professionals is not an automatic process. The 
successful implementation of these guidelines depends on a number of factors including how the 
guidelines were developed and how they were implemented into routine practice (Grimshaw and 
Russell, 1993, Grimshaw et al., 1995, Grimshaw et al., 2006).  Successful clinical guideline 
implementation requires that heath care workers change their professional behavior to adhere to the 
new guidelines. Factors that influence this required change in professional behavior are inherently 
complex (Grimshaw et al., 1995). It has been shown that passive dissemination strategies such as 
publications in professional journals can influence the level of health care workers awareness and 
knowledge of the clinical guidelines (KosecoffJ, 1987). These simple strategies have however been 
shown to be insufficient in causing sustainable behavior change in health care workers (Grimshaw et al., 
1995). More active strategies, specifically educational interventions, involving training of health care 
workers have been observed to be more likely to bring change in professional behavior (Grimshaw 
1995). Recent experiences in implementation of IMCI in developing countries have however showed 
that training alone is not enough, and that multifaceted strategies, involving training, follow up 
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al., 2005). Evidence is however insufficient to conclude on the relative effectiveness of different 
guideline implementation strategies in different contexts (Grimshaw and Russell, 1993, Grimshaw et al., 
1995, Grimshaw et al., 2006, Prior et al., 2008). 
 
Models of Health Worker Behavior Change 
The design of interventions to promote the uptake of clinical practice guidelines have drawn heavily on 
models with a basis in social and behavioral science theories. Richard Grol, in a paper in 1997  
summarized the following models that guide initiatives to influence health worker behavior (Grol, 1997). 
 
Educational Approaches 
Educational models hold that health workers are driven to change by their inherent strive for 
professional competence (Grol, 1997). Thus the strategies for change focus on stimulating this 
motivation. Examples include promoting learning from experience, problem-based learning, small group 
interactive learning and local consensus processes. The aim of these strategies is to give targeted health 
workers the feeling that they own the change process (Grol, 1997). 
 
Epidemiological Approaches 
Epidemiological approaches are based on the assumption that humans are rational beings who make 
rational decisions (Grol, 1997). This model presupposes that if health workers are provided with 
evidence of “best practice”, they will be inclined to change their practice in line with this evidence. 
Strategies based on this theory aim to synthesize and summarize evidence of “best practice” in the form 
of evidence based clinical guidelines. Key issues include credibility, soundness, and validity of the 
guidelines (Grimshaw et al., 1995).  The guideline development process should also be explicit and 
rigorous (Grimshaw et al., 1995). 
 
Marketing Approaches 
Marketing approaches emphasize the development and marketing of an attractive change proposal 
(practice change) which meets the needs of the targeted health workers and helps them to achieve their 
goals(Green et al., 1980, Rogers, 1983, Kotler and Rorberto, 1989). The message of the intended change 
is spread through a number of channels including mass media, word of mouth, professional networks, 
and the use of opinion leaders. Innovation theories, communication theories, health promotion theories 
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Behavioral Approaches 
Behavioral approaches are based on classical theories of conditioning and controlling behavior (Pervin, 
1970). Human behavior is seen as primarily influenced by stimuli before or after a specific action. 
Strategies drawing from this theory include audit and feedback, reminders, incentives and sanctions 
(Grol, 1997). 
Social Influence Approaches 
This approach holds that change is achieved as a result of the influence of, and interactions with, social 
networks (Rogers, 1983). The opinions, feedback or pressure coming from significant individuals in a 
social network have a substantial impact on whether clinical guidelines are adopted (Grol, 1997). 
Strategies based on this theory include the use of opinion leaders to diffuse information across a social 
network, outreach visits or academic detailing by respected peers or experts, peer review in small local 
groups or teams, and demonstration of new performance by colleagues (Grol, 1997). 
 Organizational Approaches 
The focus of organizational approaches is in creating the necessary conditions for change rather than on
individual performance (Berwick, 1992). Poor health worker practices are therefore seen as a system
rather than individual failure. Change strategies hence focus on fixing organizational and structural
factors hindering change (Grol, 1997). This school of thought is cognizant of the environmental and
contextual factors that influence change. 
Coercive Approaches 
Coercive approaches focus on pressure and control as a method for change (Grol, 1997). This “carrot
and stick” view informs strategies such as the development of laws and regulations, licensing and
accreditation, budgeting and contracting, performance based financing, complaints procedures, and
legal pursuits. These strategies draw their value from the fact that health workers may be stuck in their
habits and routines and hence some external pressure is needed to effect and maintain change.
Evidence of Cost Effectiveness 
Evidence of the cost effectiveness of alternative approaches to clinical guideline implementation is 
scarce, and were available, of poor quality, hardly transferable or generalizable (Prior et al., 2008, Vale 
et al., 2007, Grimshaw et al., 2004) . A systematic review by Prior and colleagues showed that the costs 
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2008). In another systematic review by Grimshaw and colleagues, of 235 studies identified, only 63 
included any information on costs (Grimshaw et al., 2004). Only 3 of the studies provided evidence of 
cost effectiveness (Grimshaw et al., 2004). The authors concluded that the studies were of poor 
methodological quality and rarely considered all relevant costs and effects (Grimshaw et al., 2004).  
 
Economic evaluations of IMCI have ranged from cost analysis, cost consequence analysis to cost 
effectiveness analysis. A cost analysis in Tanzania reported that IMCI was not associated with higher 
costs than routine child care in the four districts studied (Schellenberg et al., 2004a). Similar analysis in 
Brazil reported no statistically significant difference in the cost per child of caring for under-fives in IMCI 
municipalities (US$ 95.00) relative to the comparison municipalities (US$ 98.00) (Adam et al., 2009).  A 
study in Uganda that modeled the relationship between costs of IMCI and quality reported that that on 
the margin, investing in IMCI training at a primary facility level can yield a significant 44.3% 
improvement in service quality for a modest 13.5% increase in annual facility costs (Bishai et al., 2008). 
In Benin, a study investigating the effectiveness and efficiency of a multifaceted implementation 
strategy for IMCI reported an incremental cost-effectiveness ratio of US$ 5.30 (95% CI 3.96, 6.93) per 
additional child receiving appropriate care comparing no IMCI to IMCI plus study supports (Rowe et al., 
2009).  
  
Economic Evaluation in Health Care 
 
Economic evaluation is a technique developed to provide a framework for decision making when choices 
have to be made between several courses of action (Drummond, 2005, Fox-Rushby, 2005). It has been 
defined as the comparative analysis of alternative courses of action in terms of both costs and 
consequences (Drummond, 2005). In the context of healthcare, the alternative courses of action to be 
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The necessity to make choices is occasioned by the fact that health care resources are always scarce, 
whereas healthcare needs are unlimited (Drummond, 2005, Fox-Rushby, 2005, Gold, 1996). These 
choices are made on the basis of many criteria some of which are explicit while others are implicit. 
Economic evaluation seeks to make explicit one set of criteria that may be useful in deciding among 
different uses of scarce resources (Drummond, 2005).  
 
Types of Economic Evaluations 
There are different types of economic evaluation methodologies, characterized by the type of efficiency 
question (allocative or technical) they seek to answer and the measurement of consequences. In health 
care, a particular allocation of resources is defined to be allocatively efficient if it increases health 
outcomes in comparison to competing uses of these resources within the health sector. More narrowly, 
an allocation of resources is technically efficient if it increases health outcomes in comparison to 
alternative choices to respond to a particular need (e.g. to treat childhood illnesses). Whereas all forms 
of economic evaluation measure and present costs in monetary units, there are differences in the 




Cost Benefit Analysis 
In cost benefit analysis (CBA), benefits and costs are both valued in monetary terms (Fox-Rushby, 2005, 
Drummond, 2005). This enables the analyst to make direct comparison of a programme’s incremental 
costs and consequences in the same units of measurements (monetary) (Drummond, 2005). An 
advantage of this method of analysis is that it allows for comparisons to be made across programmes 
and sectors beyond health (Fox-Rushby, 2005). A CBA therefore answers the question of allocative 
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be made between interventions in the health sector and in the transport sector given that costs and 
effects of both interventions are presented in monetary terms. The results of a CBA are presented in a 
benefit to cost ratio. A ratio greater than 1 is favorable since it shows that the programme’s incremental 
benefits are greater than its incremental costs (Drummond, 2005). 
 
Cost Utility Analysis 
Cost utility analysis is a form of evaluation that is useful in evaluating interventions where both the 
quantity as well as the quality of life is considered important (Drummond, 2005). Examples include 
chronic diseases such as arthritis and cancer, where interest lies not just in improving survival, but also 
in the quality of life of patients with the disease.  In cost utility analysis the incremental cost of the 
programme is compared to the incremental health improvement attributable to the programme 
(Drummond, 2005). The health improvement is measured in quality adjusted life years (QALYs) or a 
variant such as the disability adjusted life year (DALYs) (Drummond, 2005, Fox-Rushby, 2005). The 
results are usually expressed as incremental cost per QALY gained or per DALY averted. The QALY and 
DALY are generic measures of health outcomes and can be obtained for different health care conditions. 
Interventions targeting different health conditions can therefore be compared in terms of their costs 
and effects. CUA can therefore answer questions of allocative efficiency within the health sector. 
 
 
Cost Effectiveness Analysis 
In cost effectiveness analysis (CEA), the incremental cost of a programme is compared to the 
incremental health effects of the programme, where the health effects are measured in natural units 
related to the objective of the programme (Drummond, 2005, Fox-Rushby, 2005). Examples of outcomes 
measures include improvement in blood pressure in mm hg, cases of disease averted or lives saved. The 
results are expressed in incremental cost effectiveness ratios (ICER) as the incremental cost per 
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the specific health intervention being evaluated, the results of CEA cannot be compared with 
evaluations of programmes targeting different health conditions. CEA therefore is designed to answer 
technical efficiency questions within specific health programmes or interventions.    
 
Cost Minimization Analysis 
When two alternative interventions are assumed to yield equivalent benefits, only costs are compared 
(Fox-Rushby, 2005). The rational choice in this case is to select the alternative with the least cost. This 
form of analysis is referred to as a cost minimization analysis (Fox-Rushby, 2005) and is a subset of CEA. 
In selecting between two blood pressure lowering drugs for example, if the effectiveness of both drugs 
in lowering blood pressure and their safety profile is equivalent, a comparison of the costs of the two 
will lead to the selection of the cheaper alternative. Like CEA, CMA will answer technical efficiency 
questions within specific health programmes.  
 
Cost Consequence Analysis 
In cost consequence analysis (CCA), health and non-health outcomes are identified and quantified, and 
are presented separately alongside the costs of the intervention (Fox-Rushby, 2005). This method was 
developed partly because of the difficulties of valuing health and non health benefits and partly because 
for certain interventions, decision makers find a single ratio (ICER) or amount (as in CBA), impenetrable 
(Fox-Rushby, 2005).  
 
Why Conduct Economic Evaluations? 
Based on the assumption that health systems have fixed budgets and competing needs, health 
resources should be allocated across interventions in such a way that the most health is generated with 
the available budget. By analyzing the efficiency of interventions, economic evaluations offer a 
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of 50% of the health budget from interventions that are less cost effective to those that are more cost 
effective could result in a 64 % increase in years of life saved in the East African region (Bobadilla, 1994 ). 
 
Framework for Economic Evaluation of Quality Improvement Interventions 
Quality improvement interventions have been conceptualized as comprised of two components (figure 
4). The treatments considered to be “best practice”, and the strategies to achieve appropriate adoption 
of these “best practices” (Freemantle et al., 1999, Mason et al., 2001, Severens, 2003, Hoomans et al., 
2009b). Their evaluation has therefore been seen as a two part evaluation; the evaluation of the 
“recommended treatment” and the evaluation of the CPG implementation strategy (Severens, 2003, 
Mason et al., 2001). Both phases are associated with benefits and costs and are thus subject to 
economic evaluation.  
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Some have argued that economic evaluation should only be done on guidelines that recommend 
treatments that have already been proven to be cost effective (Sculpher, 2000, Mason et al., 2001, 
Gandjour and Lauterbach, 2003, Gandjour and Lauterbach, 2005). Proponents of this view contend that 
interventions to implement CPGs cannot be good value for money unless the ‘good practice’ outlined in 
the CPGs is cost effective (Sculpher, 2000). For this school of thought, the evaluation of quality 
improvement interventions that employ CPGs should be done sequentially; treatment cost effectiveness 
should first be established, either by trials or modeling exercises, thereafter followed by CPG 
implementation cost effectiveness (Sculpher, 2000, Mason et al., 2001, Gandjour and Lauterbach, 2005). 
This allows for the selection of the most efficient implementation strategy for practices that are already 
proven cost effective (Freemantle et al., 1999, Sculpher, 2000). Thus the CPG implementation evaluation 
measures the change in resources required to implement the CPGs (e.g. training, development of 
manuals etc) and the health worker behaviour change achieved. These findings are combined with the 
effectiveness estimates and costs from trials, which have previously assessed treatments (Freemantle et 
al., 1999). This is outlined in figure 5.  








An alternative approach that considers decisions about guidelines and their implementation strategies 
simultaneously has also been proposed (Hoomans et al., 2009a, Hoomans et al., 2009b). In this 
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simultaneously (Hoomans et al., 2009b). This decision is based on overall estimates of the cost 
effectiveness of changing clinical practice, for different combinations of CPG and their implementation 
strategies (Hoomans et al., 2009b). Hoomans and colleagues have demonstrated that the choice to use 
either a sequential vs. a simultaneous approach affects the choice of guidelines and the implementation 
strategies adopted and argue that, in most cases, an integral approach results in more efficient resource 
utilization (Hoomans et al., 2009b). This is outlined in figure 6. 
 








Regardless of which approach is adopted, it is apparent that estimates are required of the costs and 
effects of all guidelines and of all implementation strategies under consideration.  
  
Measuring Effects 
Traditionally, generic measures such as quality adjusted life years (QALYs) and disability adjusted life 
years (DALYs) have been recommended for inclusion in cost utility analysis (Weinstein et al., 1996, 
Murray, 1994). The QALY assigns a weight between 0 (for death) and 1 (for full health) to each state of 
health and multiplies that by the number of years the health state lasts (Sassi, 2006). The DALY is a 
measure derived by adding the years of life lost due to disease (YLL) and the years of life lived with 
disability (YLD) (Murray, 1994, Anand and Hanson, 1997, Fox-Rushby and Hanson, 2001). YLL is the 
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prematurely due to disease. The YLD is calculated by assigning disability weights to health states 
between 0 (for full health) and 1 (for death) and multiplying this by the number of years the health state 
lasts (Robberstad, 2005). QALYs and DALYs are hence composite measures of health outcomes 
(mortality and morbidity). These generic measures are useful in economic evaluations due to their 
ability to enable potentially greater comparability across interventions.  
 
Evaluators of quality improvement strategies have however preferred intermediate or process measures 
over health outcome measures (Mason et al., 2001). This is due to the difficulties associated with 
measuring outcome measures which will be outlined in the next section which discusses the challenges 
in the economic evaluation of quality improvement interventions. An example of a process measure is 
the proportion for whom prescribed care follows guideline recommendations (Mason et al., 2001). In a 
systematic review of the effectiveness and efficiency of guideline dissemination and implementation 
strategies, only 5 of the 63 studies identified attempted to use patient outcomes as their primary end 
point (Grimshaw et al., 2004). The rest of the studies used process measures.  
 
Process indicators as proxies for quality of care (and therefore clinical outcomes) have already been 
used in evaluations of child health interventions including IMCI. One approach has been to develop a set 
of sick child assessment tasks that are considered important and to use this set to construct a 
continuous guideline adherence indicator on a scale of 1 to 100 (Schellenberg et al., 2004a, Chopra et 
al., 2005, Gouws et al., 2005, Rowe et al., 2009, Bishai et al., 2008, El Arifeen et al., 2004). The index of 
integrated child management developed by the WHO and used in the MCE studies is an example (Gouws 
et al., 2005, Bishai et al., 2008). A second process indicator used is a dichotomous measure of 
appropriate treatment (Rowe et al., 2009, Bryce et al., 2005a). This measure is developed by identifying 
key tasks considered critical in the management of specific diseases and scoring treatment events as 
either appropriate or not appropriate depending on whether all disease specific tasks are completed or 
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Challenges in the Economic Evaluation of Quality Improvement 
Interventions  
For simple (single) interventions such as Insecticide treated nets (ITNs) or malaria chemoprophylaxis, 
tracing costs and identifying outcomes is conceptually relatively easy, although it requires considerable 
effort and attention in practice. The (apparent) generalizability of results reported in terms of standard 
units such as the cost per DALY averted is also a major advantage in supporting decision making. 
 
Complex interventions however, present a set of challenges to economic evaluation (Shiell et al., 2008). 
The following discussion is based on the premise that multifaceted quality improvement strategies that 
incorporate clinical practice guidelines are complex, and are therefore plagued by evaluative challenges 
associated with complex interventions. Complex interventions in health care comprise a varied number 
of separate intervention elements which are all hypothesized to be essential to effectiveness (May et al., 
2007, Shiell et al., 2008, Craig et al., 2008, Rickles et al., 2007, Shepperd et al., 2009). Examples  include 
adaptation of treatment guidelines and whole community educational interventions (Medical Research 
Council, 2000). Their multiple components may act both independently and interdependently (Craig et 
al., 2008, Shiell et al., 2008, Rickles et al., 2007, Shepperd et al., 2009) and complex systems have several 
defining characteristics (Shiell et al., 2008, Rickles et al., 2007, Shepperd et al., 2009), including being: 
 
 Self organizing 
 Sensitive to initial conditions 
 Likely to undergo non-linear phase transitions 
 Often have  emergent properties : Properties of the system that are not reducible to or predictable 
from individual components and therefore require a holistic rather than a reductionist approach to 
their assessment 
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Compared to narrower clinical interventions, complex interventions are associated with a broader range 
of costs and benefits. These interventions also present difficulties in attribution, given that the causal 
chains between the intervention and effects are often long and complex and often subject to 
environmental effect modification and confounding (Victora et al., 2004, Weatherly et al., 2009).  These 
characteristics present special challenges to the process of evaluating the economic efficiency of such 
interventions (Shiell et al., 2008) that are largely methodological with respect to determining costs but 
also conceptual when considering outcomes. These challenges will be discussed in the following 
sections. 
 
Defining the Intervention  
For an intervention to be appropriately evaluated, it should be accurately and comprehensively 
described (Drummond, 2005). With complex interventions, it is more difficult to draw boundaries 
around the intervention (Shiell et al., 2008, Shepperd et al., 2009). Reviews of nearly 1,000 behavior 
change studies found that interventions were defined satisfactorily in only 5% to 30% of the 
experimental studies (Dane and Schneider, 1998, Michie et al., 2009, Gresham et al., 1993). An 
appropriate intervention description should include information on the setting where the intervention is 
delivered, the target population, the time frame, a description of intervention components, the 
frequency of delivery and the extent of coverage of the target population (World Health Organization, 
2003).  
 
Defining the Counterfactual 
Economic evaluation involves comparing an intervention to an alternative (Drummond, 2005, Gold, 
1996, Fox-Rushby, 2005). Choosing relevant alternatives to compare with quality improvement 
interventions requires care and a range of potential alternatives may be appropriate (Freemantle et al., 
1999). Possible options include “no care”, an alternative package of care or standard care (Freemantle et 
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interventions. Whereas standard care has been considered appropriate, it can sometimes be as complex 
as the intervention and change over time (Campbell et al., 2000). It is also considered unethical to 
withhold a potentially beneficial intervention from health facilities, with the implication that it may not 
be possible to use randomized study designs. Alternative approaches have included comparing an 
implementation strategy with a control group which may receive no formal intervention, but be 
passively exposed to the same material as a means of evaluating the added benefits of a more active 
approach (Nzinga et al., 2009, English et al., 2009).  
 
Analyzing Costs 
The range of costs to be considered when evaluating clinical guideline implementation interventions is 
often broad (Grimshaw et al., 2004). Systematic reviews of economic evaluations of alternative 
approaches to guideline implementation reveal variability in inclusion of different categories of costs 
(Vale et al., 2007, Prior et al., 2008). One notable feature is the omission of development costs that 
include the opportunity cost of time spent on guideline development and stakeholder meetings, among 
others (Adam, 2004). Where new guidelines are developed, as in our study in Kenya, these costs are 
often significant. Their exclusion may thus underestimate the true resource requirements of the 
intervention. Consensus is needed on how development costs should be included in such interventions.  
 
Development costs are once off, have benefits spanning beyond a year, and are often treated as capital 
costs and thus annualized (Adam, 2004). However, unlike conventional capital costs, estimating the 
useful life of these costs is subject to uncertainty and variation. Factors that increase uncertainty include 
uncertainties about the useful life of guidelines (before they become outdated) and the useful life of any 
training programmes particularly given the high turnover of trained healthcare workers in developing 
countries (Huicho et al., 2005a). Estimates of the useful life of clinical guideline have varied from 3 to 10 
years in evaluations (Shekelle et al., 2001a, Shekelle et al., 2001b). Suggestions have been to include 














It has been argued that composite measures of effectiveness such as QALYs and DALYs  are unsuitable in 
evaluating complex interventions, with examples from palliative care (Normand, 2009) and mental 
health (Chisholm et al., 1997). This is because complex interventions often have a range of benefits 
beyond health outcomes which are inadequately captured by the reductionist nature of QALYs 
(Normand, 2009) and DALYs (Sayers and Fliedner, 1997). For example, multifaceted quality 
improvement intervention such as IMCI would arguably result in changes in clinical case management 
due to adoption of evidence based practice, health worker motivation due to training and skills 
improvement, health system improvements such as improved availability of medicines and equipment 
among many others. Whereas these changes may result in better clinical outcomes, this relationship is 
non-linear. How can the full range of these benefits be captured within a DALY or a QALY? 
 
More relevant to developing countries, calculation of the DALY requires estimates of changes in 
mortality and morbidity (Anand and Hanson, 1997, Murray, 1994). While this is possible for individually 
randomized controlled trials of specific interventions, there are challenges to be overcome in measuring 
these in complex interventions which will be described briefly.  
Outcomes vs. Process Measures 
The promotion of clinical guidelines is premised on the supposition that evidence-based patient care is 
on the causal pathway to better health outcomes (English et al., 2008). Such clinical outcomes are 
commonly assessed with measures such as mortality, disease status, functional ability, and quality of life 
(Davies and Crombie, 1995). However, outcome measures such as these may be difficult to  interpret in 
the context of complex interventions which often have facilities, teams or even entire populations 
rather than the individual patient as the unit of intervention (Davies and Crombie, 1995). Hospital 
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by inadequate or poorly applied definitions, data quality, patient case-mix, clinical quality of care, 
unrecognized contextual or temporal confounding and chance (Lilford et al., 2004). Given that the study 
context is often real-life, it is much harder to control for possible confounders and effect modifiers 
compared to classical experimental RCT. Indeed the resources required for studies to demonstrate 
‘‘statistically significant’’ reductions in mortality that are credibly free from bias, residual or 
unrecognized confounding are often enormous (English et al., 2008). Because of this,  it is hard to base 
evaluations on such outcomes and as a result there is little evidence of the effectiveness of quality 
improvement initiatives (Schouten et al., 2008). These challenges perhaps explain, in part, why the IMCI 
evaluation studies in Tanzania (Schellenberg et al., 2004b), Bangladesh (Arifeen et al., 2009) and Peru 
(Huicho et al., 2005b) were unable to demonstrate significant reduction in mortality despite evidence of 
improvement in process measures. 
 
In the absence of definitive clinical outcomes data, increased use is being made of process measures as 
quality metrics to gauge intervention success (Hoomans et al., 2007, Prior et al., 2008, Grimshaw et al., 
2006, Grimshaw et al., 2004, Vale et al., 2007). Process measures are favored over outcome measures 
because they can be measured more reliably, validly and are more sensitive to differences in one 
desirable endpoint, the quality of care (Freemantle et al., 1999, Davies and Crombie, 1995, Grimshaw et 
al., 2004, Mant, 2001, Mant and Hicks, 1995, Mant and Hicks, 1996, Donabedian, 2005). Thus if 
components of clinical guidelines such as the recommended drugs have been shown elsewhere to 
improve outcomes, then process indicators that reflect the degree to which such best practice care is 
provided are themselves valid and appropriate end points (English et al., 2008). Despite the attractions 
of measuring process, these measures are valuable indicators of quality only when the processes in 
question are well supported by research evidence (Davies and Crombie, 1995). Process measures are 
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Multiplicity of Process Measures 
It will be immediately clear that a large number of processes of care measures are possible. The WHO 
index of integrated child assessment for example is constructed from 14 process indicators while the 
IMCI disease specific indicators for appropriate treatment vary in number (Gouws et al., 2005). This has 
prompted attempts to derive summary measures from process measures. A common approach to the 
selection of process measures to include in such summaries has been the use of a panel of experts to 
group related process measures based on perceived face validity (Gouws et al., 2005). This approach, 
while useful was found to lead to measures that meet face but not content or construct validity (Gouws 
et al., 2005).  
 
An alternative approach has been to employ statistical methods like principle components analysis (PCA) 
to assign indicators to appropriate groups that satisfy both face, content and construct validity (Gouws 
et al., 2005). PCA is a data reduction method that identifies coherent subsets of variables, called 
principal components, each of which might be argued to represent a particular construct (Kleinbaum, 
1998). The first principal component (PC) is the weighted linear combination of index items that explains 
the greatest variation in the original data (Gouws et al., 2005). The second PC explains the greatest 
proportion of remaining variation. Successive PCs explain as much of the remaining variance in the data 
as possible. All PC’s are linear combinations of items and are uncorrelated with each other (Kleinbaum, 
1998).  
 
Whereas PCA may allow for summary measures of process of care across individual variables to be 
created, the scoring approach derived from one study dataset cannot necessarily be applied to data 
from different contexts. Indeed it is quite likely that the same approach applied to an alternative study 
would yield different components and thus calculate summary process indices differently even if exactly 
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Variability of Process Measures 
Relevant process measures may also often vary across and perhaps even within programmes. For 
example IMCI is adapted prior to implementation to meet the needs of a specific country (Schellenberg 
et al., 2004a, Huicho et al., 2005b). In some settings care of children with malaria is of major interest, in 
others there is no malaria (Victora et al., 2005). Even within a programme different sites will have 
different patient populations, paediatric admissions in some hospitals being dominated by severe 
malaria while in others severe pneumonia is the predominant problem (English et al., 2009). This 
variability makes it difficult to compare results of evaluations across settings.  
 
Questions about which process measures to use, how they might be combined, whether weighting for 
importance or prevalence is required and how to incorporate them into a generalizable summary 
measure useful for comparative economic evaluation are still to be answered. 
 
Conclusion  
Whereas complex, “package of care” interventions that rely heavily on clinical practice guidelines are 
perceived to be effective in improving quality of care in low income settings, there is need for further 
work to develop appropriate methods for their economic evaluation. In particular, there is need for 
clearer standardization and thinking on intervention definition and choice of comparator. Evaluators 
should pay special attention to development costs and especially the opportunity costs of time spent in 
guideline development since these costs are difficult to capture. There is also need for methodological 
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More than 8.8 million children die globally before they reach the age of five. In Kenya, the under five 
mortality rate was 74 per 1000 children in 2008. To improve care for seriously ill children, a multifaceted 
approach employing guidelines, training, supervision, feedback and facilitation was developed, for 
brevity called the Emergency Triage and Treatment Plus (ETAT+). We assessed the costs and efficiency of 
the implementation of the ETAT+ strategy in district hospitals in Kenya. 
 Methods 
A cost effectiveness analysis from the provider’s perspective was conducted alongside a cluster 
randomized study that compared the implementation of ETAT+ in four district hospitals in Kenya to four 
control district hospitals receiving a partial version of the intervention between 2006 and 2008. 
Effectiveness of the intervention was measured using 14 process measures that capture improvements 
in quality of care and span the assessment, diagnosis and treatment on admission of children under five. 
Economic costs were estimated through interviews with implementers of the intervention, accounting 
and clinical record reviews. An annual discount rate of 3% was used and one way sensitivity analyses 
were used to assess uncertainty. Incremental cost effectiveness ratios (ICERs) were defined as the cost 
per percentage improvement in quality of care. 
 
Findings 
The cost per child admission was US$ 54.74 in intervention hospitals compared to US$ 31.06 in control 
hospitals, while quality of care as measured by the 14 process measures was 25.01% higher in 
intervention hospitals than in the control hospitals. These results suggest an additional cost of US$ 0.78 
to achieve a percentage improvement in quality of care. The estimated annual costs of scaling up the 
intervention to all district hospitals in Kenya was US$ 3,6 million which is 0.60 % of the annual child 
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Interpretation 
The implementation of ETAT+ as a multifaceted intervention yields significant improvements in quality 
of care but at a higher cost. The costs of scaling up the intervention appear affordable, with a very low 
budget impact. The decision to scale up ETAT+ has the potential to significantly improve the quality of 
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Background 
An estimated 8.8 million children die globally every year before the age of five [1, 2]. Ninety nine 
percent of these deaths occur in developing countries; fifty percent in Sub-Saharan Africa [1]. Most of 
these deaths are due to a few treatable and preventable diseases, for which effective interventions are 
already available [3, 4]. In 2000, United Nations (UN) member states adopted the Millennium 
Development Goals (MDGs). MDG 4 focuses on reducing the under five mortality rate by two thirds 
between 1990 and 2015.  Kenya’s under five mortality rate was 97 per 1000 live births in 1990 and rose 
to 121 per 1000 live births by 2006 [5]. The under five mortality rate then decreased to 74  per 1000 live 
births by 2008, an improvement that has been attributed in part to increased coverage of key childhood 
interventions such as immunization, insecticide treated nets (ITNs) for malaria prevention and malaria 
case management [6]. To meet the millennium development goal however, this rate has to be reduced 
further by more than 50% from the current rate to 32 per 1000 live births by 2015. There is therefore 
need for increased child survival initiatives to accelerate progress towards this target.   
 
While it is generally accepted that many child survival interventions need to be implemented at the 
community or primary care level, delivery of case management interventions for the severely ill child 
largely depends on the presence of functioning rural (district) hospitals. It has been observed that if 
functioning well, rural (district) hospitals can make an important contribution to child survival by 
reducing child mortality by 44% in the areas they serve, compared to the absence of any hospital [7, 8]. 
Unfortunately, the quality of care delivered in many district hospitals in developing countries has been 
found to be poor and in need of considerable improvement [9, 10]. Assessments of these facilities 
showed that they are characterized by unreliable availability of essential supplies such as drugs and 
equipment required for provision of child health and offer inappropriate care that is often not based on 
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One strategy for improving the delivery of care is the development and implementation of evidence 
based clinical practice guidelines (CPGs) [11]. CPGs are hypothesized to improve the quality of care by 
promoting the adoption of practices with proven benefit (best practice) and discouraging the use of 
ineffective practices [12]. It has also been shown that providing CPGs alone yields little effect, and that 
multifaceted interventions including, for example, training, feedback and supervision are more effective 
than single interventions [13-15]. 
 
To improve the quality of care for seriously ill children on admission, a multifaceted approach employing 
clinical practice guidelines, health worker training, follow up supervision, feedback and facilitation was 
developed, for brevity called the Emergency Triage and Treatment Plus (ETAT+) strategy [11, 16]. In a 
resource constrained environment, we are increasingly challenged to justify resource allocation in terms 
of costs and effects. Given the need for resources to implement clinical guideline based practice, it is 
imperative that they too be subjected to rigorous evaluation of their costs and consequences. 
Information on the costs and effects will also be useful in modeling the scale-up of the intervention to 
increase access for the population in need. The aim of this research was to analyze and present the total 
economic costs of the ETAT+ strategy, assess the efficiency of the intervention in comparison with 
passive guideline dissemination in district hospitals in Kenya, and model the costs of scaling up the 
intervention to a national level. 
Methods 
Study Design 
This was a cost effectiveness analysis alongside a cluster randomized controlled trial (cRCT). The time 
horizon selected was 18 months (September 2006 – April 2008), which was the period during which the 
intervention was implemented and evaluated.  Costing took a provider’s perspective. While this is often 
considered narrow [17, 18], for the purpose of this analysis, we considered it sufficient in encompassing 
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budgeting and planning for scale-up of the intervention in Kenya. To account for differential timing and 
time preference, we discounted costs using a 3% annual discount rate [19]. One way sensitivity analysis 
was used to assess uncertainty around hotel costs estimates, development costs, effectiveness 
estimates and staff salaries. Costs are valued and presented in 2009 US$ while effects are measured in 
terms of process indicators of quality of care that included measures of child assessment, diagnosis 
classification and treatment on admission. 
Data Collection and Sample Sizes 
In this cRCT,  8 rural district hospitals in 4 provinces in Kenya were randomized into 4 control and 4 
intervention hospitals, with the intervention hospitals receiving the full package of the interventions 
while the control hospitals received a partial version [20]. Data on clinical performance and resource use 
were collected by conducting reviews of the clinical records of children aged 2-59 months, admitted to 
these hospitals with common, acute illnesses. These data were collected at baseline and at six-monthly 
intervals in follow up surveys. In total, 6 survey rounds were completed in intervention hospitals and 4 
in control hospitals. The 2 extra surveys in intervention hospitals were conducted to assess whether the 
intervention effects were sustained in the post follow up period. Approximately 400 clinical records 
(admissions) were sampled per facility per survey. In total, clinical performance indicators were 
extracted from 1130 and 1005 clinical records at baseline and 1158 and 1157 at 18 months post 
implementation in the intervention and control hospitals respectively. Resource use data were collected 
from 6199 and 5115 clinical records for intervention and control hospitals respectively. 
 
The Intervention  
This was a package of care intervention that was delivered in the form of clinical practice guidelines 
(CPGs) dissemination, health worker training, job aids, follow up supervision and local (health facility) 
facilitation by a non-physician (nurse or diploma level) clinician. The role of the local facilitator was to 
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The CPGs were developed and adopted from existing World Health Organization (WHO) case 
management guidelines for common pediatric conditions. This includes guidelines for emergency 
pediatric care, malaria, pneumonia, asthma, diarrhea and dehydration, meningitis, malnutrition, 
HIV/AIDs and neonatal care. The training course was developed by adopting the existing WHO 
Emergency Triage, Assessment and Treatment (ETAT) course with the addition of new material on 
newborn resuscitation and common causes of serious illness in the newborn or child. This new training 
was given the name “Emergency Triage Assessment and Treatment Plus Admission Care (ETAT+)”. The 
aim of the intervention was to promote adherence to evidence based clinical practice guidelines (CPG) 
for the management of seriously ill children under five admitted to hospitals.  
 
In intervention hospitals, the intervention was delivered over 18 months as a combination of the ETAT+ 
training to health care workers conducted over 5.5 days, dissemination of CPG booklets, job aids and 
pediatric admission record (PAR) forms. The pediatric admission record (PAR) is a structured form used 
by clinicians to document a sick child’s clinical information on admission. The PAR was designed to 
capture key symptoms for common childhood illnesses (malaria, pneumonia, diarrhea and dehydration, 
meningitis, malnutrition and HIV/AIDS) as well as signs and approaches to severity classification and 
other facility information needs [21]. This was followed by 2-3 monthly supervisory visits and ad hoc 
follow-up trainings and appointment of a local facilitator in each facility that was supported by regular 
phone calls. Results and feedback reports of the surveys conducted in the facilities were disseminated in 
face to face meetings in intervention hospitals.  
 
In the control hospitals a partial version of the intervention was delivered in the form of CPG booklet 
distribution, a 1.5 day seminar and survey report feedback. Control hospitals did not receive any follow 
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An ingredients approach was used to measure costs. The costs collected included those incurred in 
development, implementation and treatment on admission of sick children in intervention and control 
hospitals. The latter are important to include as the use of CPGs may lead to changes in clinical practice 
with associated changes in the use of resources to treat sick children. Costs were collected using clinical 
and accounting record reviews and interviews with those involved in the implementation of the 
intervention. Development costs were collected for 2005-2006, annualized assuming a useful life of 4 
years, and inflated to 2009 values using GDP deflators [18, 22]. Costs of ETAT+ initial training and capital 
costs incurred during the follow up period were collected between 2006 and 2008 and annualized over 
2.5 years to reflect the annual costs of child care in the hospital. Costs were summed across all 
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Guideline Development Costs 
Development costs included costs incurred in the development of ETAT+ guidelines, adaptation of the 
guidelines and training materials. Data sources for this information included accounting records, 
researcher’s log books and interviews with persons involved with these activities. The opportunity cost 
of time spent on these activities was estimated as the proportion of salaries of persons carrying out the 
activities based on the time allocated to the activity. Economic costs for tradable items were estimated 
from market prices. Development costs were annualized over 4 years which was considered to be the 
useful life of the clinical guidelines and associated development costs. 
 
Guideline Implementation Costs 
Guideline implementation costs included the costs of initial ETAT+ training of health workers, follow up 
training, supervisory visits and phone calls, feedback meetings and onsite local facilitator costs. The 
opportunity costs of resources used in these activities were evaluated. For example, the opportunity 
cost of staff time used in attending training and meetings were estimated as the proportion of salaries 
of persons attending the trainings based on the time allocated to the activity. The costs of the initial 
training were considered to be capital costs given that the effects of the training were expected to be 
realized over a period of more than one year. These costs were annualized over a useful life of 2.5 years, 
which was the length of time over which the training effects were seen to be sustained, based on the 
two additional surveys at 6 months intervals in intervention hospitals. Follow up activities and 
supervision were considered to be recurrent costs.  
 
Treatment Costs 
Treatment costs were collected because it was anticipated that the intervention would result in changes 
in these costs. Treatment costs were computed as the sum of “hotel”, medicines and laboratory costs 
per admission. Per day “Hotel” costs were derived from the World Health Organization, “Choosing 
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inpatient care in Kenya [5, 23]. The WHO CHOICE estimates represent the “hotel” component of hospital 
costs, excluding drugs and diagnostic tests and including other costs such as personnel, capital and food 
costs [24]. Medicine unit costs were derived from 2009 market prices while unit costs of diagnostic tests 
were derived from laboratory costing estimates from a local district hospital, Kilifi District hospital. 
Utilization data for patient length of stay in hospital, medicines and laboratory tests were collected from 
patient clinical records. Given the skewed nature of cost data, treatment costs are presented in both 
means (and confidence intervals) and medians (and interquartile ranges). 
 
Presenting, Annualizing and Transferring Costs over Time 
Costs were adjusted for inflation using GDP deflators for Kenya [25]. Given the fluctuations in exchange 
rates within the time horizon, costs were first converted from Kenyan Shillings (KES) to USD using the 
respective periods’ mean annual exchange rates, before inflation to the base year to minimize currency 
fluctuation effects [26]. 
 
Evaluating Effectiveness 
We used process indicators of quality of care to estimate the effectiveness of the intervention. This is in 
line with the Donabedian framework which proposes that quality of care can be measured by assessing 
either the structure, process or outcomes of care [27]. In total there are 14 indicators that span three 
broad areas: assessment of a severely ill child, therapeutic care and supportive care on admission. These 
indicators cover the diseases that result in 60% of inpatient deaths in children under 5 in Kenya. These 
measures were selected based on feasibility and one or more of: a clear, logical link to patient 
outcomes; a clear and proximate link to the intervention; requirement for minimal resource inputs; or, 
objectivity of the assessment(s) (English et al 2008).  For any one child, 3-7 indicators would apply 
depending on diagnosis and severity of disease. We defined dichotomous variables for process errors 
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and a continuous variable (range 0-1) to summarize assessment tasks to an aggregate assessment score 
for each child. 
 
 The effectiveness of the intervention was obtained by comparing the intervention and control hospitals 
at survey 4 using a two-stage method. In the first stage, logistic or linear regression analyses were 
conducted for each of the 14 process measures adjusting for hospital-level covariates (all-cause 
paediatric mortality, malaria transmission, and size) and gender, illness outcome (alive or died) at the 
patient-level. The observed events were then subtracted from predicted events in the regressions to 
obtain a residual for each cluster. The cluster residuals were then compared in the second stage using a 
t-test [20].  
 
For purposes of the cost effectiveness analysis, the measure of effect was the mean of the adjusted 
differences between control and intervention hospitals at 18 months which represents the mean 
percentage improvement in the 14 process of care indicators in intervention compared to control 
hospitals. The summary measure of effectiveness (mean percentage improvement in process 
measures/quality of care) was computed as outlined in figure 8: 
 











Q =  
Where: 
Q: Mean percentage improvement in process of care 
Ei: Adjusted difference of each process of care between control and intervention hospitals 
at 18 months 
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Assessing Efficiency 
The incremental cost effectiveness ratio (ICER) was defined as the incremental cost per percentage 
improvement in quality of care. This is the ratio of the difference in admission cost per child between 
intervention and control hospitals, and the difference in percentage improvement in process measures 
of quality between control and intervention hospitals (figure 9). The ICER thus represents the additional 
cost per percentage improvement in quality of care.  







Total Costs of Scale Up 
Kenya has 121 district hospital facilities spread around the country with an estimated annual pediatric 
admission of 2000 per facility, hence an estimated annual total pediatric admission of 242,000. We 
estimated cost of scaling up this multifaceted quality of care intervention with the assumption that 
development costs do not change with scale up, training costs vary as a function of the number of 
facilities while other implementation costs vary as a function of the number of pediatric admissions. We 
assumed that the intervention would reach all relevant hospitals when at scale.  
 
Sensitivity Analysis 
One way sensitivity analysis was used to assess uncertainty around estimates for effectiveness, “hotel” 
costs, development costs and staff salaries. Intervention effectiveness was varied between 3.54% and 











Page | 65  
 
hospitals across the 14 process measures, with 3.54 % being the smallest reported improvement 
(Proportion of gentamicin prescriptions with daily dose greater than 10mg/kg) and 52.10% the greatest 
reported improvement (Proportion of malaria episodes with a severity classification). “Hotel” unit cost 
estimates used in the base case were the WHO-CHOICE estimate for district hospitals in Kenya, inflated 
to 2009 to give US$ 6.96 per day [28], while the estimate used for the sensitivity analysis was from a 
Kenyan study inflated to 2009 to give US$ 15.05 per day (Nganda et al 2003). We considered scenarios 
where the development cost was not included in the analysis and a scenario where the full development 
cost was included.  We also considered a scenario where the salaries of the intervention implementers 
(based on salary scales of a non government organization that implemented the intervention) included 
in the base case analysis were replaced with local government salaries which are significantly lower. We 
also include an analysis of a hypothetical status quo scenario where costs are incurred for guideline 
development and dissemination but there is no training or follow up supervisory activities. This status 
quo scenario reflects the case in most developing countries. 
Results 
Intervention Costs 
Total intervention costs and admission costs per child in intervention and control hospitals are 
presented in table 1. Development and ETAT+ training costs were 15.98 % and 7.84% respectively, of 
total intervention costs in i tervention hospitals. An average of 32 health workers underwent the initial 
ETAT+ training at a cost of US$ 8069.32 per intervention hospital and hence the training cost per heath 
worker was US$ 252.16. Follow up activities (follow up training, supervision and local facilitator costs) 
were 19.89 % of total intervention costs in intervention hospitals. The annual costs of a local facilitator 
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Table 1 Summary of Intervention Costs 
 INTERVENTION HOSPITALS  CONTROL HOSPITALS  










COST PER PATIENT 
US$ 
AS % OF TOTAL 
INTERVENTION 
COSTS 
START-UP COSTS       
DEVELOPMENT COSTS 16,227.46 8.11 15.98 9,898.29 4.95 15.93 
TRAINING MATERIAL COSTS 692.92 0.35 0.69 0.00 0.00 0.00 
TOTAL START-UP COSTS 16,920.39 8.46 16.67 9,898.29 4.95 15.93 
IMPLEMENTATION COSTS       
INITIAL TRAINING 8,069.32 4.03 7.94 2,017.33 1.01 3.25 
FOLLOW UP ACTIVITIES       
FOLLOW UP TRAININGS 4,348.05 2.17 4.28 0.00 0.00 0.00 
LOCAL FACILITATOR COSTS 5,697.87 2.85 5.62 0.00 0.00 0.00 
SUPERVISION COSTS 10,135.50 5.07 9.99 0.00 0.00 0.00 
TOTAL FOLLOW UP COSTS 20,181.42 10.09 19.89 0.00 0.00 0.00 
TOTAL IMPLEMENTATION COSTS 28,250.73 14.13 27.85 2,017.33 1.01 3.25 
START-UP & IMPLEMENTATION 45,171.11 22.59 44.52 11,915.62 5.96 19.19 
TREATMENT COST 56,304.79 28.15 55.48 50,202.30 25.10 80.81 
TOTAL INTERVENTION COSTS 101,475.90 50.74  62,117.92 31.06  




An ordinary linear (OLS) regression of treatment costs revealed that costs did not significantly vary with 
child diagnosis, hospital and time (three six monthly intervals between baseline and follow up at 18 
months). We therefore pooled treatment costs across surveys and diagnosis within each study arm 
(intervention hospitals and control hospitals) to increase sample sizes. We however also present costs in 
their disaggregated form. Treatment costs per admission episode in intervention and control facilities 
are presented in table 2. “Hotel” costs were the key driver of treatment costs and contributed between 
73.18 % and 79.98 % of treatment costs.  Admission treatment costs for specific diagnosis are presented 
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Table 2 Treatment Costs per Admission  
 INTERVENTION HOSPITALS CONTROL HOSPITALS 
COST ITEMS N MEDIAN COST 
US$(IQR) 
MEAN COST US$ 
(95%CI) 
AS A % OF 
TREATMENT 
COSTS 
n MEDIAN COST 
US$(IQR) 
MEAN COST US$ 
(95%CI) 
AS A % OF 
TREATMENT 
COSTS 
HOTEL COSTS 4,963 18.64 (9.55-23.88) 22.54 (21.99-23.09) 73.18 % 4,460 14.33 (9.55-23.88) 20.90 (20.36-21.44) 79.98 % 
DRUG COSTS 5,514 1.68 (0.72-3.00) 2.51 (2.43-2.59) 8.15 % 4,460 1.11 (0.43-2.29) 1.80 (1.73-1.86) 6.89 % 
LAB COSTS 6,199 3.36 (0.00-3.36) 5.63 (5.52-5.75) 18.28 % 5,115 3.36 (0.00-3.36) 3.33 (3.23-3.44) 12.74 % 
TREATMENT COSTS 5,678 22.47 (14.33-32.78) 28.15 (27.61-28.70)  4,691 19.25 (13.01-29.04) 25.10 (24.56-25.65)  
 
Table 3 Admission Treatment Costs per Diagnosis 
  INTERVENTION HOSPITALS CONTROL HOSPITALS 




N MEDIAN LOS 
(IQR) 
MEAN LOS  
(95% CI) 
MALARIA 956 3(2-5) 3.89 (3.62-4.17) 1029 2(2-4) 3.26  (3.08-3.44) 
PNEUMONIA 508 4(2-5) 4.32 (3.94-4.53) 634 4(2-6) 4.50  (4.18-4.81) 
DIARRHEA & DEHYDRATION 221 3(2-5) 3.71 (3.31-4.11) 225 3(2-5) 4.33  (3.87-4.81) 
PNEUMONIA & MALARIA 1175 3(2-5) 3.96 (3.78-4.13) 719 3(2-5) 4.00  (3.73-4.29) 
PNEUMONIA & DIARRHEA 70 3(2-5) 4.49 (3.57-5.40) 77 4(2-6) 4.70  (3.79-5.61) 
MALARIA & DIARRHEA 396 3(2-5) 3.70 (3.38-4.01) 354 3(2-5) 3.68  (3.39-3.97) 
MALARIA & PNEUMONIA & DIARRHEA/DEHYDRATION 188 4(2-5) 4.19 (3.75-4.62) 80 4(2-5) 4.34  (3.52-5.15) 
POOLED AGGREGATE 5241 3(2-5) 4.27 (4.16-4.37) 4628 3(2-5) 4.02 (3.92-4.13) 
 
Table 4 Average Length of Stay in District Hospitals  
  INTERVENTION HOSPITALS CONTROL HOSPITALS 




N MEDIAN LOS 
(IQR) 
MEAN LOS  
(95% CI) 
MALARIA 956 3(2-5) 3.89 (3.62-4.17) 1029 2(2-4) 3.26  (3.08-3.44) 
PNEUMONIA 508 4(2-5) 4.32 (3.94-4.53) 634 4(2-6) 4.50  (4.18-4.81) 
DIARRHEA & DEHYDRATION 221 3(2-5) 3.71 (3.31-4.11) 225 3(2-5) 4.33  (3.87-4.81) 
PNEUMONIA & MALARIA 1175 3(2-5) 3.96 (3.78-4.13) 719 3(2-5) 4.00  (3.73-4.29) 
PNEUMONIA & DIARRHEA 70 3(2-5) 4.49 (3.57-5.40) 77 4(2-6) 4.70  (3.79-5.61) 
MALARIA & DIARRHEA 396 3(2-5) 3.70 (3.38-4.01) 354 3(2-5) 3.68  (3.39-3.97) 
MALARIA & PNEUMONIA & DIARRHEA/DEHYDRATION 188 4(2-5) 4.19 (3.75-4.62) 80 4(2-5) 4.34  (3.52-5.15) 
POOLED AGGREGATE 5241 3(2-5) 4.27 (4.16-4.37) 4628 3(2-5) 4.02 (3.92-4.13) 
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Changes in Process of Care Measures 
The mean of the adjusted difference in difference in changes in the 14 process measures between 
control and intervention hospitals was 25.01%. The findings of performance changes across all process 
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Table 5 Average Performance in Control and Intervention Hospitals at Baseline and 18 Months Follow-up and Adjusted Difference (95%CI) at 18 
Months 
INDICATOR OF QUALITY OF CARE INTERVENTION CONTROL ADJUSTED 
DIFFERENCE 
BETWEEN 
GROUPS AT 18 
MONTHS* (%) 
95%CI P VALUE 
 
 
PROCESS INDICATORS  SURVEY 1 SURVEY 4 SURVEY 1 SURVEY 4    
CHILD'S WEIGHT DOCUMENTED 59.30 84.50 21.00 63.20 22.80 -4.05 49.70 0.080 
CHILD'S TEMPERATURE DOCUMENTED  11.90 71.90 25.10 46.60 26.50 -4.49 57.50 0.080 
AVERAGE ASSESSMENT SCORE 24.00 94.00 32.00 65.00 29.00 5.00 54.00 0.030 
PROPORTION OF PNEUMONIA EPISODES WITH A SEVERITY CLASSIFICATION 9.29 95.10 14.70 57.00 38.57 9.87 67.30 0.017 
PROPORTION OF GENTAMICIN PRESCRIPTIONS WITH ONCE DAILY DOSE 1.85 89.20 3.54 74.40 17.05 8.04 26.10 0.004 
PROPORTION OF GENTAMICIN PRESCRIPTIONS WITH DAILY DOSE <4MG/KG 24.90 2.16 23.40 8.99 6.77 -11.90 -1.59 0.019 
PROPORTION OF GENTAMICIN PRESCRIPTIONS WITH DAILY DOSE >=10MG/KG 3.78 6.25 7.15 9.82 3.54 -11.10 4.00 0.294 
PROPORTION WITH ADEQUATE OXYGEN PRESCRIPTIONS 0.00 37.00 0.00 2.31 35.10 7.32 62.80 0.021 
PROPORTION OF MALARIA EPISODES WITH A SEVERITY CLASSIFICATION 10.10 92.50 2.48 41.10 52.10 26.20 78.00 0.003 
PROPORTION OF SEVERE MALARIA WITH QUININE LOADING 4.20 91.90 14.80 66.70 26.30 -3.66 56.30 0.075 
PROPORTION OF SEVERE MALARIA WITH TWICE DAILY QUININE MAINTENANCE DOSE 0.39 87.80 9.95 45.70 42.60 25.10 60.20 0.001 
PROPORTION OF SEVERE MALARIA WITH QUININE DAILY DOSE >=40MG/KG 7.33 1.02 14.10 7.46 6.53 -12.90 -0.20 0.045 
PROPORTION OF DEHYDRATION EPISODES WITH A SEVERITY CLASSIFICATION 52.40 98.30 60.50 84.80 14.40 4.27 24.60 0.013 
CORRECT INTRAVENOUS FLUID PRESCRIPTION  7.32 67.20 15.00 40.60 29.90 10.90 48.90 0.008 
MEAN CHANGE IN QUALITY OF CARE 13.79 58.98 15.15 39.24 25.01    
* Adjusted difference between intervention arms obtained from linear or logistic regression analysis of hospital summary data adjusting for child’s sex, illness outcome and hospital factors 
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Incremental Costs, Effects and Cost Effectiveness Analysis 
The incremental cost per admission in intervention hospitals compared to control hospitals was US$ 
19.68 .The incremental cost per percentage improvement in quality of care was US$ 0.78 per child 
admission. These results are presented in table 6.   
Table 6 Cost Effectiveness Analysis 
STRATEGY MEAN ADMISSION 
COSTS PER CHILD US $ 
INCREMENTAL 
COST US $ 
EFFECTS(% CHANGE IN 
QUALITY OF CARE) 
INCREMENTAL EFFECTS (% 




31.06  24.09   
FULL 
INTERVENTION 
50.74 19.68 45.20 25.01 0.78 
 
Estimated Costs of Scale-Up and Budget Impact 
For an estimated coverage of 121 district hospitals and 242,000 annual under 5 admissions, the 
estimated costs of scale-up were found to be US$ 3,633,123.45. This is estimated to be equivalent to 
0.60 % of the 2010 annual budget for provision of care to children under 5 in Kenya (Table 7).  
Table 7 Total Costs of Scale-Up 




STATUS QUO**  
US$ 
NO OF DISTRICT HOSPITALS 121 121 121 
ESTIMATED ANNUAL PEDIATRIC ADMISSION DISTRICT 
HOSPITALS IN KENYA 
242,000 242,000 242,000 
COSTS OF NATIONAL SCALE UP  3,633,123.45 321,186.32 79,186.32 
BUDGETED COSTS FOR PROVISION OF UNDER 5 CHILD HEALTH 
SERVICES IN KENYA IN 2010* 
572,000,000.00 572,000,000.00 572,000,000.00 
 IMPACT OF SCALING UP ETAT+ ON THE ANNUAL CHILD 
HEALTH BUDGET 
0.60% 0.06 0.02 
*Estimates of annual costs (2010) of provision of care to children under five derived from the Kenya national health sector 
strategic plan 2 (NHSSP II) 
**The status quo scenario assumes that CPG are developed and disseminated without any training or follow up activities as is 
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Sensitivity Analysis 
The ICERs were found to vary between US$ 0.38 and US$ 5.56 per percentage improvement in quality of 
care, with one way sensitivity analysis. Scale up costs varied from US$ 2,635,833.65 to US$ 3,633,123.45 
(Table 8). 
Table 8 Sensitivity Analysis 
ONE-WAY SENSITIVITY TEST ICER SCALE UP COSTS US$ 
BASE CASE 0.78 3,633,123.45 
LOW EFFECTIVENESS ESTIMATE (3.54%) 5.56 3,633,123.45 
HIGH EFFECTIVENESS ESTIMATE (52.10%)  0.38 3,633,123.45 
DEVELOPMENT COSTS – OMISSION OF DEVELOPMENT COSTS 0.66 3,503,303.73 
HOTEL COSTS – USE OF A HIGHER HOTEL COST  
ESTIMATE FROM A LOCAL STUDY  
0.89 3,633,123.45 
SALARIES – USE OF MINISTRY OF HEALTH LOCAL SALARY RATES 0.66 2,635,833.65 
 
Findings of Incorporating a Hypothetical Status Quo Alternative 
The incremental cost effectiveness ratio (ICER) of the partial intervention (in control hospitals) 
compared to a hypothetical status quo alternative was US$ 0.05 per percentage improvement in quality 
of care as shown in table 9.  
 
 Table 9 Cost Effectiveness Analysis with Hypothetical Status Quo Option as the Base Case Comparator 
STRATEGY MEAN ADMISSION 






(% CHANGE IN QUALITY 
OF CARE) 
INCREMENTAL EFFECTS  
(% CHANGE IN QUALITY OF CARE) 
(ICER) 
STATUS QUO 30.42  10.00   
PARTIAL 
INTERVENTION 
31.06 0.64 24.09 14.09 0.05 
FULL 
INTERVENTION 
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Discussion 
This analysis compares the costs and effects of a guideline based intervention aimed at improving the 
quality of care of children in district hospitals in Kenya. In analyzing the costs, we included the costs of 
developing clinical guidelines which are often left out in such analysis (Grimshaw et al 2004). 
Development costs are comprised mainly of the opportunity cost of time spent in designing the 
intervention, and of synthesizing and compiling evidence that formed the basis of the clinical guidelines. 
These costs, in intervention hospitals, also included costs of training ETAT+ instructors and pilot training 
of ETAT+, making them higher compared to control hospitals. Our analysis revealed that development 
costs formed 15.98 % of the overall intervention costs. This finding suggests that these items should be 
included in future analyses as they are important cost drivers. On average, 32 health workers were 
trained in each intervention hospital hence the training cost per health worker is US$ 252.16. This cost  
is significantly lower than heath worker training costs for similar interventions such as IMCI where the 
reported median cost was US$ 633 [29] and malaria case management training with an estimated cost 
of US$ 1266 [30]. One strategy that was used to contain training costs was not paying allowances to 
participants of the training in contrast to common practice in developing country settings. 
 
One of the unique components of this intervention was the appointment of a local facilitator in 
intervention hospitals. This was a non-physician (diploma level clinician or nurse) health worker whose 
role was to offer supervisory and on-site problem solving support to the facilities in implementing the 
intervention. The annual cost of this facilitator per facility was US$ 5,697.87. The local facilitator worked 
at the facility for the entire intervention period. This provided continuity and helped to keep the “quality 
agenda” on the table. This was considered important as it was observed that staff turnover is often 
significant in health facilities in Kenya. Indeed only 26 % of the health workers initially trained in 
intervention hospitals were still in the hospitals providing paediatric care at the time of our major 
endpoint (survey 4) [20]. Thus of a total 109 clinical staff responsible for paediatric admission events 
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ad hoc training [20]. Such turnover resulted from staff transfers to other hospitals, internal staff rotation 
between clinical departments, scheduled rotation of clinical staff linked to training requirements 
(internships) and, where there were staff shortages, reallocation of clinical staff away from paediatric 
and newborn areas [31]. In such settings, an intervention that involves only a one-off training without 
follow up and efforts to institutionalize best practice is unlikely to have a sustained effect. This highlights 
the fact that in order to achieve sustained and meaningful change in professional practice, interventions 
must aim at changing organizational culture, over and above changing individual health worker 
professional practice. The fact that this intervention was shown to have a sustained effect even when 
almost all the health workers trained had left strongly suggests that a change in organizational culture 
was achieved.  
 
Treatment costs were found to be higher in intervention hospitals compared to control hospitals, with 
the disaggregated analysis indicating that this was driven by higher costs for malaria admissions in 
intervention hospitals. Hotel costs were found to be between 73.18 % and 79.98 % of total treatment 
cost suggesting that the length of stay in hospital is the main driver of treatment costs. Interventions 
that would result in significant reductions in hospital length of stay will therefore be expected to be cost 
saving. We have assumed that the WHO CHOICE hotel cost estimates are a reasonable proxy for hotel 
costs for district hospitals in Kenya. However, by using this cost for all hospitals, we are in effect 
assuming that there are no major differences in the intensity of staffing per patient. This assumption 
was justified in that we did not expect that our intervention would require different levels of health 
worker input within the different hospital settings. However, we acknowledge this as a potential 
shortcoming to this research.  
 
If one were to consider that the process of caring for a sick child involves a number of critical steps, 
including correctly assessing the child on presentation, making the right diagnosis which includes a 










74 | P a g e  
 
frequency), then the intervention can be seen to have improved the process, and hence quality, of care 
across these key steps. Child assessment for example improved by 29.00 % (95 % CI 5.00-54.00) and the 
proportion of children with a severity classification improved by 38.57 % (95 % CI 9.87-67.30) and 52.10 
% (95% CI 26.20-78.00) for children with pneumonia and malaria respectively. Prescription and 
administration of appropriate therapies was also seen to improve as demonstrated by a 35.10 % (95 % 
CI 7.32-62.80) improvement in adequate oxygen prescriptions, 42.60 % (95 % CI 25.10-60.20) 
improvement in children receiving twice daily quinine maintenance and 29.90% (95 % CI 10.90-48.90) 
improvement in intravenous fluid prescriptions. These processes of care were specified in the clinical 
guidelines which were disseminated in both the control and intervention hospitals and hence both 
groups of hospitals had the opportunity to implement them. There is strong evidence therefore for 
substantial improvements in quality of care as a result of the intervention. An argument can therefore 
be made that dissemination of clinical guidelines passively is not enough, and that more proactive follow 
up and supervisory support is required in order to ensure significant and sustained uptake of clinical 
guidelines. This is consistent with similar observations made in the implementation of IMCI in Uganda 
where training alone was found to be insufficient to change health worker practice [13]. 
 
To assess efficiency, we defined the Incremental cost effectiveness ratio (ICER) as the cost per 
percentage improvement in quality of care as measured from the mean of the 14 process of care 
measures in control and intervention hospitals. The incremental cost per child admission in the 
intervention hospitals compared to the control hospitals was 19.68 US$ while the incremental effects 
(percentage improvement in quality of care) was 25.01 %. It is clear therefore that the more effective 
strategy is also more expensive. Our findings suggest an additional cost of US$ 0.78 per child admitted 
to achieve a percentage improvement in quality of care. Adopting the ETAT+ strategy therefore results 
in improvements in quality of care of sick children but at an additional cost, which will require increasing 
the current budget for child health or reallocating resources from other activities to meet the budgetary 
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Also of importance is assessing the costs of scaling up, which provides insights into the feasibility of 
implementation of ETAT+ on a national scale. Kenya has 121 district hospitals with an estimated annual 
under five admission of 2000 per facility. The intervention at scale is therefore targeted at an estimated 
242,000 under five admissions per annum. We estimated that it would require US$ 3,633,123.45 to 
scale up the intervention to a national level. In modeling costs of scale up, we assumed that 100 % 
coverage of the intervention will be achieved. This is admittedly overly optimistic as in reality, 100 % 
coverage of interventions is rarely achieved. While scaling up could result in significant economies of 
scale, larger economies of scale are expected to be achieved with efficient scale up strategies. Activities 
such as supervision and follow up could for example be tied to already existing district level supervisory 
activities resulting in shared costs with other activities. 
 
The Kenyan ministry of medical services estimates that it spends US$ 572,000,000.00 on the provision of 
care to children under five [32]. Scaling up the ETAT+ intervention nationally is therefore estimated to 
require 0.60 % on the child health budget. This means that in order to scale up the intervention, either 
the child health budget will have to be increased by 0.60 % or allocations to one or a group of activities 
within the budget will have to be reduced by an amount equivalent to the cost of scale up. With a 0.60 
% impact on Kenya’s annual child budget, the impact of ETAT+ scale up on the national budget is a 
fortiori much lower. Scaling up ETAT+ nationally is hence arguably an affordable investment with 
expected significant improvements in quality of care provided to children in district hospitals. 
 
Testing the sensitivity of this analysis to changes in effectiveness leads to wide variations in the ICER 
(US$ 0.38 to US$ 5.56 per percentage improvement in quality of care). This suggests that the efficiency 
of the intervention is sensitive to the effectiveness of the intervention. When intervention 
implementer’s salaries are replaced by local government salaries, the ICER is reduced by 15.00 % and 
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significant variable in the efficiency and costs of the intervention. When WHO CHOICE hotel costs were 
substituted with costs from a local study, the ICER increased by 13.00 %.  
 
We considered a hypothetical “status quo” where guidelines are developed and passively disseminated, 
and compared this to the partial intervention in control hospitals and full intervention in intervention 
hospitals. The status quo represents a scenario, which is common in developing countries, where clinical 
practice guidelines are developed and passively disseminated. No form of training or follow activities is 
undertaken. Indeed this is a generous description as experience in Kenya shows that for a long time 
clinical guidelines for management of sick children were available but no strategies were put in place for 
their distribution. The ICER of the partial intervention compared to the hypothetical status quo scenario 
was US$ 0.05 per percentage improvement in quality of care. This finding implies that the partial 
intervention as delivered in control hospitals is more efficient than the full intervention as delivered in 
intervention hospitals, which has an ICER of US$ 0.78 per percentage improvement in quality of care.  
This finding is due to the fact that the partial intervention is being compared to a costly but highly 
ineffective alternative (status quo), making the incremental costs between the partial intervention and 
status quo scenario minimal while the incremental effects between the two are large. This highlights the 
fact that ICERs of interventions in economic evaluations are influenced by what the intervention is being 
compared with and thus should always be interpreted within this context.   
 
It has been observed that the economic evaluation of complex package of care interventions is 
associated with challenges in defining an appropriate effectiveness measure [33]. While conventionally, 
CEA’s  have used outcome indicators such as life years gained or generic measures such as QALYs and 
DALYs, it has been observed that these measures are often not sensitive to changes occasioned by 
complex interventions and do not capture the broad range of benefits that would potentially accrue 
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(mortality and morbidity) which, for complex interventions, are difficult to assess due to the complex 
causal chains between intervention and outcomes and the potential for residual and unrecognized 
confounding. Designing studies to measure these “hard” outcomes will also require large sample sizes 
that are expensive and rarely feasible in developing countries. In this analysis, we defined the 
effectiveness of the intervention as changes in process of care measures, in line with the Donabedian 
framework for quality measurement that considers quality as a triad of structure, process and outcome 
[27]. This approach has been used elsewhere in the evaluation of guideline based quality of care 
interventions [15, 34]. Process of care measures have been used to measure adherence to CPGs as the 
main endpoint for CPG implementation [35]. Others have extended this approach by defining measures 
of appropriate care based on observed or documented clinician practices [36]. A major limitation of this 
approach is that it fails to clearly bring out the value of the intervention to the patients and by extension 
to decision makers. There is need for a more explicit link between process measures and health 
outcomes. One suggestion would be to model treatment outcomes from intermediate outcomes like 
appropriate care. This could for example be achieved by using structured elicitation techniques like 
Delphi exercises to obtain expert opinions on, for instance, the difference in risk of death if a child with 
complicated malaria receives “appropriate care” compared with the same child receiving “inappropriate 
care”. More importantly, given that this and similar complex quality of care interventions are designed 
to target improvements over a range of benefits beyond clinical outcomes, perhaps a method of valuing 
these interventions that encompasses more than health outcomes is more appropriate.  Exploring the 
utility of process of care by for example eliciting society’s preferences for the spectrum of process 
attributes of such interventions and the value they place on improvements in process of care will be key 
in informing decisions to adopt quality of care interventions. 
 
Should the intervention be scaled up? The decision on whether or not to adopt ETAT+ in Kenya should 
be informed not only by efficiency assessments, but also other criteria such as  the costs of scale up and 
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considering affordability, the total cost of the intervention at scale is seen to have a low impact (0.60 %) 
on the annual child health budget and therefore can be argued to be affordable. Component costs, such 
as ETAT+ training are also seen to be relatively more affordable compared to similar health worker 
training initiatives like IMCI, malaria and HIV case management.  
 
Improving the delivery of evidence based care for common childhood diseases responsible for the 
greatest mortality is likely to contribute to improved child survival. This intervention has been shown to 
significantly improve the quality of care for admitted children in district hospitals. Given that children 
are an especially vulnerable group in society, interventions that target improvement in their survival can 
be argued to contribute to improving equity in health in the population. The fact that this intervention 
targets diseases responsible for the highest number of deaths in children under five means that 
investing in the scaling up of ETAT+ is likely to result in the greatest health gains among children under 
five and hence improved technical efficiency. Promoting strategies to improve delivery of care for 
children in Kenya is expected to improve child survival and hence accelerate progress towards achieving 
millennium development goal (MDG) 4. There is therefore a strong case for the scaling up of the ETAT+ 
intervention in Kenya. 
 
A major limitation of this study is the use of process of care as measures of outcome in economic 
analysis. The use of a process of care summary measure to assess the efficiency of the intervention, 
rather than generic outcome measures such as the DALY and QALY, presents challenges in the 
interpretation of the ICER and commenting on the cost effectiveness of the intervention. Because these 
measures are unique to this intervention, it is not possible to compare the results from this intervention 
to other cost-effectiveness or cost-utility studies. This points to the need for methodological 
development work for appropriate effectiveness measures for quality of care interventions, where 
health outcome changes cannot be demonstrated.  The summary measure was also computed with the 
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debatable. It is more likely that different processes vary in relative importance and significance in the 
care of the sick child. Another limitation of this study is that a provider perspective has been used. It has 
been argued that this is a narrow view and that a societal perspective would be more encompassing [18, 
28]. These limitations notwithstanding, this analysis presents findings that at best lay out to decision 
makers the costs of the intervention, the expected improvements in process of care and the budgetary 
implications of the intervention at scale. It can also be looked at as a partial analysis that would inform a 
broader modeling of the value for money of the intervention.  Further work will include modeling the 
linkages between process improvements and health outcomes, and determining the utility of processes 
of care. This will involve developing an effectiveness measure that captures changes beyond clinical 
outcomes and encompassing process (of care) utility. 
 
Conclusion  
This analysis has shown that adopting the ETAT+ strategy is more effective in improving quality of care 
compared to a partial version of the intervention that did not include the full training, follow up and 
supervisory support. These additional supports including a local facilitator are seen to lead to a 
sustained improvement in quality of care in intervention facilities. This work has also highlighted the 
methodological challenges in the economic evaluation of complex interventions, specifically quality of 
care interventions, were outcomes are multiple and demonstrating health outcomes in not always 
possible. There is therefore need for further work in developing better approaches to economic analysis 
of such interventions, and specifically in developing more appropriate effectiveness measures for such 
analyses.  
 
Concerning methodological extensions to this work, we have proposed the modeling of health outcomes 
from process of care measures, which would allow the analysis and presentation of economic evaluation 
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suggestion is to investigate and establish the value society places on quality improvement and their 
preferences for technical process of care. Determining the existence and magnitude of “process of care 
utility” of this and similar interventions will perhaps provide a better basis for assessing the value for 
money for such interventions. These results are likely to be generalizable only to low income countries 
with similar district health characteristics, child burden of disease, and comparable quality of delivery of 
pediatric care in hospitals as Kenya. 
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In the year 2000 UN member states adopted 
the Millennium Development Goals (MDGs) 
among them MDG 4 which calls for a two thirds 
reduction in the number of children dying 
before the age of five between 1991 and 2015. 
In Kenya, the number of children dying before  
age five was 97 per 1000 children born in 1990 
and by 2006 had risen to 121 per 1000 children 
born (Ayieko et al., 2009). This number then 
substantially decreased  to 74 per 1000 children 
born by 2008 (Kenya National Bureau of 
Statistics (KNBS) and ICF Macro, 2010). Most of 
these child deaths are caused by few treatable 
and preventable diseases, mainly pneumonia, 
diarrheal diseases, malnutrition and malaria for 
which proven and affordable interventions are 
available (Jones et al., 2003). These deaths are 
still unacceptably high and to achieve the MDG 
target, will need to reduce by more than 50 % 
to 32 per 1000 children born by 2015. There is 
therefore a need to enhance efforts to improve 








The district hospital has been considered a 
critical avenue for the delivery of child saving 
interventions. It has been suggested that 
improving their performance would reduce 
child mortality by 3-30 % in the areas they serve 
(English et al., 2004). It has however been 
shown that the quality of care delivered in 
these hospitals in Kenya is poor (English et al., 
2004). Assessments of these facilities have 
revealed that often they do not have essential 
supplies such as drugs and equipment and the 
care for admitted children is not based on 
current knowledge and evidence. 
One strategy for improving quality of care is 
promoting the use of clinical guidelines that are 
based on current evidence. Clinical guidelines 
improve quality of care by promoting the use of  
Box 1: Key Findings and Recommendations 
 ETAT+ was shown to improve the quality 
of care children admitted in hospitals by 
25.01 %  
 The total cost of scaling up ETAT+ is 
estimated to be US$ 3,633,123.45 
 
 This cost is estimated to be only 0.60 % 
of annual child health budget in Kenya 
 
 ETAT+ is effective, affordable and should 
there be scaled up to all district hospitals 
in Kenya 
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practices of proven benefit and discouraging 
ineffective and outdated practices. To improve 
the quality of care of children admitted in 
district hospitals in Kenya, clinical guidelines for 
the provision of care to admitted children were 
developed and implemented in selected district 
hospitals. The implementation of this guideline 
was accompanied by 5.5 days of training for 
health workers, job aids and follow up 
supervision.  A local facilitator was also 
appointed in the hospital to provide on-site 
supervision. This intervention was for brevity 
called the Emergency Triage and Treatment Plus 
(ETAT+) strategy. We present here the findings 
of an assessment of the costs and 
consequences the ETAT+ strategy. 
Research Objective 
This research assessed the costs and 
consequences of implementing the ETAT+ 
strategy in district hospitals in Kenya. This was 
compared with partial implementation of the 








dissemination and a short seminar (1.5 days). 
The research also looks at the costs of scaling 
up the intervention and the impact this scaling 
up will have on the child health budget in 
Kenya. 
Methods 
The intervention was delivered over 18 months 
(September 2005- April 2008) in 4 district 
hospitals in Kenya. The partial version of the 
intervention was delivered to 4 other district 
hospital for comparison.  The costs of the 
intervention were obtained as the sum of the 
costs of developing and implementing the 
intervention as well as treating admitted 
children. The major outcome of the 
intervention was quality of care delivered to 
children admitted in hospital. We estimated the 
costs that would be required to scale up the 
intervention to all the 121 district hospitals in 
Kenya and looked at the impact of this cost on 
the annual child health budget. 
Findings 
 The total cost of the intervention for each 
intervention hospital was US$ 101,475.90 
POLICY BRIEF 
Box 2: Package of Interventions Developed and Delivered to Intervention Hospitals 
1. Evidence based clinical guidelines for management of pediatric conditions, developed with the Kenyan 
ministry of medical services and other key stakeholders 
2. Job aids: Clinical guideline booklets, drug dosing, fluid and feed charts, structured pediatric admission 
forms 
3. A 5.5 day health worker training on an extended version of the WHO ETAT training in line with developed 
CPG (ETAT+)  
4. Follow up supervisory support through visits every 2-3 months 
5. Appointment of a local facilitator (Clinical officer or nurse) in each facility to provide onsite supervisory and 
problem solving support 
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which translates to a cost of US$ 50.74 per 
child admitted 
 
 The cost of ETAT+ training per health care 
worker was found to be US$ 252.16 while 
the annual cost of a local facilitator per 
hospital was US$ 5,697.87 
 
 The intervention resulted in a 25.01% 
improvement in quality of care  
 
 The estimated cost of scaling up the 
intervention to all 121 district hospitals in 
Kenya is US$ 3,633,123.45 
 
 This cost of scaling up is estimated to be 
0.60 % of the  child health budget for Kenya; 
The estimated budget for provision of child 
health services in Kenya for 2010 is US$ 
572,000,000.00 (MOH, 2005). 
What Do These Finding Mean? 
It was observed that the intervention resulted 
in significant improvements in the quality of 
care of sick children admitted in hospital. For 
instance, the assessment of children by the 
clinician on admission improved by 29.00 % 
while the correct prescription and 
administration of medicines was also seen to 
improve as demonstrated by a 35.10 % 
improvement in adequate oxygen prescriptions, 
42.60 % improvement in children receiving 
twice daily quinine maintenance dose and 29.90 
% improvement in intravenous fluid 
prescriptions. 
Experience in the implementation of the 
Integrated Management of Childhood Illnesses  
(IMC) revealed that that disseminating clinical 
guidelines passively is not enough (Pariyo et al., 
2005). It was shown that training health 
workers should be augmented by follow up and 
supervision for there to be a sustained effect. 
This research demonstrated this to be true in 
Kenya and highlighted the importance of 
support and supervision of health workers in 
implementing clinical guidelines.  
A unique addition to this intervention was the 
appointment of a non-physician local facilitator 
in each facility. This was a diploma level clinician 
(clinical officer) or nurse whose role was to 
offer on-site supervision and problem solving 
support. This was considered important given 
that the turnover of heath workers in public 
health facilities is high in Kenya. Indeed it was 
observed that only 26 % of health workers 
originally trained in hospitals were still present 
after 18 months. The facilitator offered 
continuity by helping to keep the “quality 
agenda” on the table. This served to develop 
and institutionalize a quality culture that 
resulted in a sustained improvement in quality 
of care despite the high staff turnover. 
 
Scaling up the ETAT+ strategy to all district 
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increase in the annual child health budget. 
ETAT+ at scale is therefore highly affordable 
and results in only a minimal addition to the 
child health budget. At a cost of US$ 252.16 per 
health worker, the health worker training is 
cheaper than similar trainings like Integrated 
Management of Childhood Illnesses (IMCI) 
(US$633) (Rowe et al., 2008) and malaria case 
management (US$ 1266) (MOMS and MOPHS, 
2010). When this affordability is considered 
together with the potential improvements in 
quality of care for children in hospitals, ETAT+ is 
arguably very good value for money and should 
be scaled up.  
This intervention also targets child survival and 
hence is likely to improve equity in health in 
Kenya. Children are a vulnerable group in the 
population and bear the brunt of diseases of 
high burden such as malaria and pneumonia. 
The ETAT+ strategy targets diseases of high 
burden children that are responsible for more 
than 60% of childhood deaths. This includes 
malaria, pneumonia, diarrhea and dehydration, 
malnutrition and neonatal care. Investing in the 
intervention will hence lead to greater gains in 
health improvement among children and hence 
improve allocation of child health resources.  
Policy Recommendation 
Scale up of ETAT+ 
We recommend that the government and 
development partners prioritize the delivery of 
evidence based clinical guidelines for admitted 
children in hospitals as a key strategy to 
improve child survival. In line with this, 
resources should be committed for the scaling 
up of pediatric guideline dissemination, ETAT+ 
training, and sustainable structures, including 
human resources, put in place for the 
supervision and support of quality of care 
activities. 
 
Monitoring of Quality of Care 
As part of the improvements in the national 
health management information system 
(HMIS), quality of care should be integrated in 
the monitoring and reporting of hospitals. This 
can be achieved by developing and 
incorporating quality of care parameters and 
including them as part of the routine data 
collected and reported by facilities. This will 
however only be useful if systems are in place 
to appropriately analyze and feedback and act 
on the findings of such monitoring initiatives. 
 
Institutionalizing Quality of Care 
To assure sustainability of quality of care 
improvements, the government needs to take 
concrete steps to institutionalize the quality of 
care agenda in public hospitals. This can be 
done by recognizing quality as an important 
performance indicator for facilities and 
developing responsibility and accountability 
structures in the public hospitals to assure 
quality.  One way to achieve this would be to 
create the position of a “quality manager” 
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be to direct and support quality initiatives 
within the hospitals. Our findings showed that 
this is an affordable and effective strategy to 
supporting quality initiatives. 
With the adoption of performance contracting 
in the public health sector in Kenya, another 
strategy for institutionalizing quality of care is 
for the government to integrate provision of 
quality of care as part of performance targets 
for health workers. Quality of care should also 
be included as part of the performance 
evaluation of facilities. This should however be 
done transparently and with significant 
involvement of front line health workers and 
facility representatives. This will avoid 
perceptions of bias, unfairness and eventual 
loss of motivation of health workers.  As 
discussions continue about introducing 
performance based financing of health facilities 
in Kenya, quality of care should be incorporated 
as a key performance benchmark. 
    
Incorporate ETAT+ Into Pre-service Training  
To ensure sustainability and improved 
intervention coverage, ETAT+ training should be 
included as part of the curriculum during the 
training for non degree (clinical officers and 
nurses) and degree level (medical student at 
undergraduate and master’s level) clinicians. 
This will also in the long term reduce the costs 
of in-service training of health workers.  
Managing Staff Turnover 
While we cannot belabor the need for 
government to retain health workers in the 
public sector, special recommendations need to 
be made here for the government and perhaps 
more relevantly, public hospital managers to 
put in place strategies to minimize inter 
departmental staff turnover within public 
hospitals. While the government and 
development partners spend significant 
amounts of resources on in-service training of 
health workers, high staff turnover significantly 
reduces the effectiveness of this investment.  
Specifically for child health a policy for 
cultivating health worker specialization should 
be adopted. Clinicians and nurses who have 
been trained to provide care for sick children 
for example, should be retained in pediatric 
departments to continue providing this care.    
Conclusion 
The ETAT+ strategy has been shown to 
significantly improve the quality of care of 
children in district hospitals in Kenya. Our 
findings show that scaling up the strategy 
nationally is very affordable while the potential 
benefits that could accrue are significant. A 
decision by the government of Kenya to invest 
in the adoption of ETAT+ on a national scale will 
therefore provide great value for money. This 
will no doubt go a long way in improving child 
survival in Kenya and accelerate progress 
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Part E: Appendices 
Appendix 1:  Clinical Record Data Abstraction Tool 
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Appendix 2: Intervention Implementers Time Quantification Tool 
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 Figure legends (if any) 
 Tables and captions (if any) 
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Title page  
This should list the title of the article. The title should include the study design, for example: 
A versus B in the treatment of C: a randomized controlled trial 
X is a risk factor for Y: a case control study 
The full names, institutional addresses, and e-mail addresses for all authors must be included on the title 
page. The corresponding author should also be indicated. 
Abstract  
The abstract of the manuscript should not exceed 350 words and must be structured into separate 
sections: Background, the context and purpose of the study; Methods, how the study was performed 
and statistical tests used; Results, the main findings; Conclusions, brief summary and potential 
implications. Please minimize the use of abbreviations and do not cite references in the abstract; Trial 
registration, if your research article reports the results of a controlled health care intervention, please 
list your trial registry, along with the unique identifying number, e.g. Trial registration: Current 
Controlled Trials ISRCTN73824458. Please note that there should be no space between the letters and 
numbers of your trial registration number. We recommend manuscripts that report randomized 
controlled trials follow the CONSORT extension for abstracts. 
Background  
The background section should be written from the standpoint of researchers without specialist 
knowledge in that area and must clearly state - and, if helpful, illustrate - the background to the research 
and its aims. Reports of clinical research should, where appropriate, include a summary of a search of 
the literature to indicate why this study was necessary and what it aimed to contribute to the field. The 
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Methods 
This should include the design of the study, the setting, the type of participants or materials involved, a 
clear description of all interventions and comparisons, and the type of analysis used, including a power 
calculation if appropriate. 
Results and Discussion
The Results and Discussion may be combined into a single section or presented separately. Results of 
statistical analysis should include, where appropriate, relative and absolute risks or risk reductions, and
confidence intervals. The results and discussion sections may also be broken into subsections with short, 
informative headings.
Conclusions
This should state clearly the main conclusions of the research and give a clear explanation of their
importance and relevance. Summary illustrations may be included.
List of abbreviations
If abbreviations are used in the text, either they should be defined in the text where first used, or a list 
of abbreviations can be provided, which should precede the competing interests and authors'
contributions.
Competing interests  
A competing interest exists when your interpretation of data or presentation of information may be 
influenced by your personal or financial relationship with other people or organizations. Authors should 
disclose any financial competing interests but also any non-financial competing interests that may cause 
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Authors are required to complete a declaration of competing interests. All competing interests that are 
declared will be listed at the end of published articles. Where an author gives no competing interests, 
the listing will read 'The author(s) declare that they have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
 In the past five years have you received reimbursements, fees, funding, or salary from an 
organization that may in any way gain or lose financially from the publication of this manuscript, 
either now or in the future? Is such an organization financing this manuscript (including the article-
processing charge)? If so, please specify. 
 Do you hold any stocks or shares in an organization that may in any way gain or lose financially from 
the publication of this manuscript, either now or in the future? If so, please specify. 
 Do you hold or are you currently applying for any patents relating to the content of the manuscript? 
Have you received reimbursements, fees, funding, or salary from an organization that holds or has 
applied for patents relating to the content of the manuscript? If so, please specify. 
 Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, religious, ideological, academic, 
intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify. 
If you are unsure as to whether you or one of your co-authors has a competing interest, please discuss it 
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Authors' contributions  
In order to give appropriate credit to each author of a paper, the individual contributions of authors to 
the manuscript should be specified in this section. 
An "author" is generally considered to be someone who has made substantive intellectual contributions 
to a published study. To qualify as an author one should 1) have made substantial contributions to
conception and design, or acquisition of data, or analysis and interpretation of data; 2) have been
involved in drafting the manuscript or revising it critically for important intellectual content; and 3) have
given final approval of the version to be published. Each author should have participated sufficiently in
the work to take public responsibility for appropriate portions of the content. Acquisition of funding,
collection of data, or general supervision of the research group, alone, does not justify authorship.
We suggest the following kind of format (please use initials to refer to each author's contribution): AB
carried out the molecular genetic studies, participated in the sequence alignment and drafted the
manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES
participated in the design of the study and performed the statistical analysis. FG conceived of the study,
and participated in its design and coordination and helped to draft the manuscript. All authors read and
approved the final manuscript.
All contributors who do not meet the criteria for authorship should be listed in an acknowledgements
section. Examples of those who might be acknowledged include a person who provided purely technical
help, writing assistance, or a department chair who provided only general support.
Authors' information  
You may choose to use this section to include any relevant information about the author(s) that may aid 
the reader’s interpretation of the article, and understand the standpoint of the author(s). This may 
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or any other relevant background information. Please refer to authors using their initials. Note this 
section should not be used to describe any competing interests. 
Acknowledgements and Funding  
Please acknowledge anyone who contributed towards the study by making substantial contributions to 
conception, design, acquisition of data, or analysis and interpretation of data, or who was involved in 
drafting the manuscript or revising it critically for important intellectual content, but who does not meet 
the criteria for authorship. Please also include their source(s) of funding. Please also acknowledge 
anyone who contributed materials essential for the study. 
The role of a medical writer must be included in the acknowledgements section, including their source(s) 
of funding. 
Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements. 
Please list the source(s) of funding for the study, for each author, and for the manuscript preparation in 
the acknowledgements section. Authors must describe the role of the funding body, if any, in study 
design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the 
decision to submit the manuscript for publication. 
References  
All references must be numbered consecutively, in square brackets, in the order in which they are cited 
in the text, followed by any in tables or legends. Reference citations should not appear in titles or 
headings. Each reference must have an individual reference number. Please avoid excessive referencing. 
If automatic numbering systems are used, the reference numbers must be finalized and the bibliography 
must be fully formatted before submission. 
Only articles and abstracts that have been published or are in press, or are available through public e-
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communications should not be included in the reference list, but may be included in the text and 
referred to as "unpublished data", "unpublished observations", or "personal communications" giving the 
names of the involved researchers. Notes/footnotes are not allowed. Obtaining permission to quote 
personal communications and unpublished data from the cited author(s) is the responsibility of the 
author. Journal abbreviations follow Index Medicus/MEDLINE. Citations in the reference list should 
contain all named authors, regardless of how many there are. 
Preparing tables 
Each table should be numbered in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should 
also have a title that summarizes the whole table, maximum 15 words. Detailed legends may then 
follow, but should be concise. 
Smaller tables considered to be integral to the manuscript can be pasted into the document text file. 
These will be typeset and displayed in the final published form of the article. Such tables should be 
formatted using the 'Table object' in a word processing program to ensure that columns of data are kept 
aligned when the file is sent electronically for review; this will not always be the case if columns are 
generated by simply using tabs to separate text. Commas should not be used to indicate numerical 
values. Color and shading should not be used. 
Larger datasets can be uploaded separately as additional files. Additional files will not be displayed in 
the final, published form of the article, but a link will be provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls) or comma 
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